SEQUENCE VARIANTS IN THE RYR1 GENE AND GENETIC DISEASES: MALIGNANT HYPERTHERMIA AND CONGENITAL MYOPATHIES by Perrotta, Giuseppa
  
 
 
 
 
 
SEQUENCE VARIANTS IN THE RYR1 
GENE AND GENETIC DISEASES: 
MALIGNANT HYPERTHERMIA AND 
CONGENITAL MYOPATHIES 
 
 
Giuseppa Perrotta 
 
 
 
 
 
 
 
 
Dottorato in Scienze Biotecnologiche –XXII ciclo 
Indirizzo Biotecnologie Mediche 
Università di Napoli Federico II  
 
 
 
 
 
 
 Dottorato in Scienze Biotecnologiche – XXII ciclo 
Indirizzo Biotecnologie Mediche  
Università di Napoli Federico II  
 
 
 
 
 
 
 
 
 
 
SEQUENCE VARIANTS IN THE RYR1 
GENE AND GENETIC DISEASES: 
MALIGNANT HYPERTHERMIA AND 
CONGENITAL MYOPATHIES 
 
 
Giuseppa Perrotta 
 
 
 
Dottoranda: Dr.ssa Giuseppa Perrotta 
 
Relatore:  Prof.ssa Antonella Carsana 
 
Coordinatore: Prof. Ettore Benedetti 
  
 
 
 
 
 AKNOWLEDGEMENTS 
 
I would like to acknowledge my supervisor, Prof. Antonella Carsana, who guided me through 
this project with her scientific attitude and gave me the opportunity to learn many things. I 
was very fortunate to work in a friendly research group. I am very grateful to my colleagues 
that made my Ph.D time a fruitful and joyful experience. Special thanks to Dr. Alberto Zullo 
for his scientific contribute and also for many relaxing and fun moments. Endless thanks to 
my parents, my sister, my brother and my grandmother for their love and support through the 
years.  
 
 
 TABLE OF CONTENTS 
  
SUMMARY   pag.    1 
RIASSUNTO    pag.    2 
1 INTRODUCTION pag.    6  
1.1 Ryanodine receptor 1 (RYR1) pag.    6  
1.1.1 Stucture and topology pag.    6   
1.1.2 Gating of RYR1 pag.    8  
1.2 RYR1 in excitation-contraction (E-C) coupling  pag.   10   
1.3  Modulation of RYR1 activity pag.   11 
1.3.1 RYR1 and regulatory proteins pag.   12   
Cav 1.1 channel pag.   12    
Calmodulin (CaM) pag.   13   
FKBP12 pag.   14    
Calsequestrin, triadin and junction pag.   14  
Other proteins pag.   16    
1.3.2 Endogenous modulators of RYR1 pag.   16   
Calcium pag.   16   
ATP and Mg2+ pag.   16 
Redox modifications pag.   16    
Phosphorylation pag.   16   
1.3.3 Exogenous modulators of RYR1 pag.   17   
Ryanodine pag.   17    
Caffeine pag.   17   
Local anesthetics pag.   17   
Volatile anesthetics pag.   18    
4-Chloro-m-cresol pag.   18   
Ruthenium red pag.   18    
Dantrolene pag.   18   
1.4 RYR1-related diseases pag.   18    
1.4.1 Malignant hyperthermia (MH)  pag.   19   
Etiology pag.   19    
Diagnosis  pag.   20    
Genetic basis pag.   20    
Genetic testing pag.   21 
 1.4.2  Congenital myopathies pag.   23   
1.4.2.1 Central Core Disease (CCD) pag.   24 
Diagnosis  pag.   25    
Genetic basis pag.   25    
1.4.2.2 Multiminicore Disease (MmD) pag.   26   
Diagnosis  pag.   27   
Genetic basis pag.   27   
1.4.2.3 Nemaline rod Myopathy (NM) pag.   28   
Diagnosis  pag.   28    
Genetic basis pag.   28   
1.4.2.4 Centronuclear myopathy (CNM) pag.   29   
Genetic basis pag.   29   
1.4.2.5 Congenital neuromuscular disease with uniform Type 1 fibers     
(CNMDU1) 
pag.   30    
Genetic basis pag.   30    
1.4.2.6 Congenital fiber type disproportion (CFTD) pag.   30   
Genetic basis pag.   30   
1.4.3 Molecular mechanisms in RYR1-related core myopathies 
 
pag.   30    
1.4.4 Risk of MH associated with core myopathies 
 
pag.   33  
2 AIMS OF THE WORK AND EXPERIMENTAL DESIGN pag.   34    
3 MATERIALS AND METHODS pag.   35    
3.1 Patients pag.   35   
3.2 Genomic DNA extraction pag.   35    
3.3 Polymerase Chain Reaction (PCR) pag.   35   
3.4 Denaturing high performance liquid chromatography 
(dHPLC) 
pag.   39    
3.5 DNA sequence pag.   40   
3.6 EBV-transformed B-lymphocytes pag.   40   
3.6.1 Production of the Epstein-Barr Virus pag.   40   
3.6.2 Mononuclear cell isolation pag.   40   
3.6.3 EBV infection of human B-lymphocytes pag.   41   
3.7 RNA extraction from EBV-immortalized B-lymphocytes pag.   41   
3.8 cDNA synthesis pag.   41   
3.9 Semi-quantitative PCR pag.   42   
3.10 Capillary gel electrophoresis (CGE) pag.   43   
 3.11 Proton release assay pag.   43   
3.12 Calcium release assay pag.   43    
3.13 Statistical analysis pag.   45 
4 RESULTS pag.   46    
4.1 Molecular characterization of DNA sequence variants pag.   49  
4.1.1 Molecular characterization of the double variant S3098I 
and   F4924_V4925insRQGVALLPFF 
pag.   50   
Effects of F4924_V4925insRQGVALLPFF insertion on the 
structure of the RYR1 channel 
pag.   51    
Transcription analysis pag.   53  
mRNA semi-quantitative analysis pag.   55   
4.2 Functional characterization of sequence variants pag.   57  
Proton release measurements pag.   57    
Calcium release measurements pag.   58    
5 DISCUSSION pag.   61 
REFERENCES pag.   63   
APPENDIX   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 LIST OF ABBREVIATIONS 
 
 
 
4-CmC  4-chloro-m-cresol 
Å Angstrom 
ACTA1 α-actin gene 
ATP Adenosine triphosphate 
BSA Bovine serum albumin 
Ca2+ Calcium ion 
CaM Calmodulin 
Cav Voltage-gated calcium 
CCD Central core disease 
cDNA Complementary DNA 
CFTD Congenital fiber type disproportion 
CICR Calcium induced calcium release  
CMs Congenital myopathies 
CNM Centronuclear myopathy 
CNMDU1 Congenital neuromuscular disease with uniform Type 1 fibers             
CFL2 Cofilin 2 
CryoEM Cryo-electron microscopy 
CSQ Calsequestrin  
CY Cytoplasmic 
DHP Dihydropyridine 
dHPLC Denaturing high performance liquid chromatography 
DHPR  Dihydropyridine receptor  
EBV Epstein-Barr virus 
E-C Excitation-contraction 
EDTA Ethylene diamine tetra-acetic acid 
EGTA Ethylene glycol tetraacetic acid 
ER Endoplasmic reticulum  
FBS Fetal bovin serum  
FKBP12 12 kDa FK506-binding protein 
Fura-2/AM Fura-2 acetoxymethyl ester  
GT Gomori trichrome 
HEK-293 Human embryonic kidney 293 cells 
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IL Interleukin 
IVCT In vitro contracture test 
K+ Potassium ion 
[Ca2+]i Intracellular calcium concentration 
IP3 Inositol 1, 4, 5-trisphosphate 
Mg2+ Magnesium ion 
MH Malignant hypethermia  
MHE Malignant hypethermia equivocal  
MHN Malignant hypethermia normal  
MHS Malignant hypethermia susceptible 
MIM Mendelian inheritance in man 
MmD Multi-minicore disease 
 MRI Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
MYH7 β-myosin heavy chain gene 
Na+ Sodium ion 
NEB Nebulin gene 
NM Nemalinic myopathy 
NO Nitric oxide 
PBS Phosphate-buffered saline  
RYRs Ryanodine receptors 
RYR1 Ryanodine receptor type 1 
RYR1 RYR1 gene 
RYR2 Ryanodine receptor type 2 
RYR3 Ryanodine receptor type 3 
SEPN1 Selenoprotein N1 gene 
SOC Store-operated channel 
s.e.m. Standard error of the mean  
SR Sarcoplasmic reticulum  
T-tubule Transverse tubule  
TM Transmembrane 
Tn Troponin 
TPM2 β-tropomyosin gene 
TPM3 α-tropomyosin gene 
TNNT1 Troponin T1 
TTN Titin gene 
wt Wild-type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 1 
SUMMARY 
 
This PhD thesis has been focused on the identification and functional 
characterization of sequence variants in the RYR1 gene, associated with Malignant 
hyperthermia (MH) and some congenital myopathies (CMs). MH is an autosomal 
dominant pharmacogenetic disorder caused by an altered intracellular Ca2+ 
homeostasis. This pathology shows a life treatening hypermetabolic crisis after 
administration of anaesthetics and/or depolarizing muscle relaxants. MH is 
syntomatologic silent and until now the only sensitive and specific test for the 
diagnosis of MH is the in vitro contracture test (IVCT), carried out on muscle 
byopsies. MH presents wide genetic heterogeneity: six genetic loci associated with 
the MH suscettible phenotype (MHS) have been identified. In more than 70% of MHS 
patients the locus segregating with the pathology is MHS-1, where the RYR1 gene 
maps. The RYR1 gene codifies for the ryanodine receptor type 1 (RYR1), a calcium 
release channel localised in the sarco/endoplasmic reticulum (SR/ER) membrane of 
skeletal muscle and B-lymphocytes. CMs are a heterogeneous group of inherited 
neuromuscular disorders characterized by hypotonia and muscle weakness, that 
usually present at birth or early childhood or rarely adulthood. Myophathies linked to 
RYR1 mutations are differentiated on the basis of the histopathological features in: 
core myopathies (central core disease, multiminicore disease, nemaline rod 
myopathy, and centronuclear myopathy), characterized histologically by central 
cores, multi-minicores, nemaline rods, central nuclei in muscle fibers, respectively; 
and others myopathies (congenital neuromuscular disease with uniform Type 1 
fibers, and congenital fiber-type disproportion myopathy) characterized histologically 
by the almost exclusive presence of Type 1 muscle fiber and relative hypotrophy of 
type 1 muscle fibers, respectively. Great phenotypic and histopathological overlap 
and marked phenotypic variability are present in different myopathies. So far more 
than 200 sequence variants have been identified in the RYR1 gene, but only 28 
variants have been investigated for their functional effect and included in the 
guidelines for molecular genetic detection of MH susceptibility (www.emhg.org).  
In this study, the mutation analysis of the RYR1 gene was performed by Denaturing 
High Performance Liquid Chromatography (dHPLC) and automatic sequencing in 24 
MHS subjects, one CCD patient and one with minicores. 14 RYR1 gene sequence 
variants, an in-frame insertion variant and several known and novel polymorphisms 
have been identified. We characterized the effect of nine RYR1 variants on the 
channel function. The functional characterization was performed by two in vitro 
assays, proton and calcium release assays, on Epstein-Barr virus immortalized B-
lymphocytes from patients carrying the sequence variants. The results showed 
alterations in the functional activity of the RYR1 mutated channel. 
 
 
 
 
 
 
 
 
 
 2 
RIASSUNTO 
 
Questo lavoro di tesi è stato incentrato sull’identificazione e sull’analisi funzionale di 
varianti di sequenza nel gene RYR1, associate all’Ipertermia Maligna (MH) e ad 
alcune miopatie congenite: miopatia Central Core (CCD), miopatia Multiminicore 
(MmD), miopatia nemalinica (NM), miopatia centronucleare (CNM), miopatia 
congenita neuromuscolare con prevalenza di fibre di tipo 1 (CNMDU1) e miopatia 
congenita con alterata proporzione dei tipi di fibre (CFTD). L’MH è una malattia 
neuromuscolare, a trasmissione autosomica dominante nell’uomo, è dovuta ad 
un’alterata regolazione del calcio intracellulare e si manifesta con una crisi 
ipermetabolica potenzialmente letale in seguito alla somministrazione dei più comuni 
anestetici e miorilassanti depolarizzanti in soggetti geneticamente suscettibili (MHS). 
L’MH mostra un’elevata eterogeneità genetica, sono stati, infatti, identificati sei loci 
genici (MHS1 MIM 180901, MHS2 MIM 154275, MHS3 MIM 154276, MHS4 MIM 
600467, MIM MHS5 601887, MHS6 MIM 601888) associati al fenotipo MHS. In più 
del 70% dei pazienti MHS è stata trovata associazione con il locus MHS1, dove 
mappa il gene RYR1 che codifica il canale di rilascio del calcio RYR1 presente sul 
reticolo sarco/endoplasmatico (SR/ER) del muscolo scheletrico e dei linfociti B. 
L’unico test sensibile e specifico accettato dalla comunità scientifica per la diagnosi 
di MH è un saggio di contrazione in vitro (IVCT) che valuta ex vivo  la contrazione di 
fibre muscolari sottoposte a trattamento con alotano e caffeina. La CCD è una rara 
miopatia congenita raramente progressiva, a trasmissione autosomica dominante, 
caratterizzata da ipotrofia e ipotonia nell’età infantile. La diagnosi clinica è effettuata 
mediante analisi istologica di campioni derivati da biopsie muscolari che presentano 
numerose aree circolari amorfe, definite cores, caratterizzate da basso numero di 
mitocondri, ridotta attività enzimatica ossidativa e disorganizzazione dei sarcomeri 
nelle fibre di tipo I. La MmD è una condizione clinicamente eterogenea, trasmessa 
come carattere autosomico recessivo, le cui caratteristiche generali includono 
ipotonia neonatale, sviluppo ritardato del sistema motorio, debolezza muscolare 
generale e amiotrofia che può lentamente progredire o rimanere stabile. La biopsia 
muscolare mostra piccole aree multiple caratterizzate da disorganizzazione dei 
sarcomeri e perdita di mitocondri a carico sia delle fibre di tipo I che di tipo II. La NM 
è una rara malattia neuromuscolare ereditaria caratterizzata generalmente da 
debolezza muscolare non progressiva di gravità variabile. Le principali manifestazioni 
cliniche comprendono debolezza muscolare, ipotonia e riflessi tendinei profondi, 
assenti o ridotti. La malattia è ereditata come tratto autosomico dominante e 
autosomico recessivo. La diagnosi è confermata mediante analisi istologica di 
campioni derivati da biopsie muscolari che presentano nel citoplasma delle fibre 
muscolari piccole strutture bastoncellari (nema in greco significa proprio bastoncello), 
costituite da aggregati di proteine (α-actinina), e in alcuni casi anche i cores. La CNM 
è una malattia neuromuscolare ereditaria la cui trasmissione può essere X-linked 
recessiva, autosomica dominante e recessiva. Il quadro clinico è altamente variabile. 
La biopsia muscolare mostra la presenza di nuclei al centro delle fibre muscolari 
anziché alla periferia, spesso circondati da un alone chiaro, con disposizione a 
catenella nelle fibre osservate longitudinalmente. Queste fibre assomigliano ai 
miotubi, cioè alle fibre muscolari nelle prime fasi dello sviluppo maturativo, che hanno 
appunto i nuclei centrali. Inoltre, in alcune fibre si evidenziano anche i cores. La 
CNMDU1 è una rara forma di miopatia congenita caratterizzata dalla prevalenza di 
fibre muscolari di tipo 1 (>99%). Clinicamente, la CNMDU1 mostra le caratteristiche 
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tipiche di una miopatia congenita, con debolezza muscolare nell’età infantile. La 
CFTD è una rara miopatia caratterizzata da ipotrofia delle fibre di tipo 1, la cui 
trasmissione può essere X-linked recessiva, autosomica dominante e recessiva. I 
pazienti con CFTD mostrano ipotonia e debolezza muscolare generalizzata di gravità 
variabile. Quindi la diagnosi di tutte queste miopatie si basa sull’analisi istopatologica 
delle biopsie muscolari e sui segni clinici evocativi. 
Finora sono state identificate più di 200 mutazioni puntiformi nel gene RYR1 che 
segregano con l’MH (la maggior parte), CCD, MmD e in numero minore con le altre 
miopatie congenite descritte. Solo per alcune mutazioni è stata dimostrata la 
correlazione con il fenotipo malattia, mediante saggi in vitro che valutano le 
alterazioni nella funzionalità dei canali RYR1 mutati, e 28  di esse sono riportate dalle 
linee guida 2009 del Gruppo Europeo dell'MH (www.emhg.org) come causative del 
fenotipo MHS e/o CCD. Tali saggi sono anche per effettuare correlazioni genotipo-
fenotipo.  
I principali saggi descritti in letteratura valutano il rilascio del Ca2+ da parte di RYR1 
in risposta ad agenti scatenanti e prevedono l’utilizzo di colture di miotubi o di linfociti 
B immortalizzati derivati da pazienti portatori di mutazioni in eterozigosi o 
transfezione ed espressione di cDNA di RYR1 mutati in cellule HEK-293 o in miotubi 
provenienti da soggetti normali. Per la valutazione del rilascio di calcio citoplasmatico 
sono stati utilizzati degli indicatori fluorescenti in grado di legare il calcio libero e 
sistemi microfisiometrici che misurano la variazione di attività metabolica cellulare 
come rilascio protonico extracellulare. 
Nel presente progetto di tesi è stata utilizzata la tecnica della cromatografia in fase 
liquida ad alte prestazioni in condizioni semi-denaturanti (dHPLC) per l’analisi di 
mutazioni in 26 soggetti, di cui 24 MHS, uno affetto da CCD e uno da MmD. L’analisi 
di mutazioni ha portato all’identificazione di 14 varianti di sequenza, un’inserzione in-
frame e molti polimorfismi. Tutte le varianti di sequenza sono state caratterizzate 
molecolarmente e nove di esse sono state anche caratterizzate funzionalmente 
mediante saggi in vitro. Nove varianti di sequenza [c.1589G>A (p.R530H), 
c.1840C>T (p.R614C), c.6488G>C (p.R2163P), c.6502G>A (p.V2168M), c.6635T>A 
(p.V2212D), c.7025A>G (p.N2342S), c.7361G>A (p.R2454H), c.11708G>A 
(p.R3903Q) and c.12700G>C (p.V4234L)] sono state precedentemente identificate 
anche da altri gruppi di ricerca in soggetti MHS. In questo lavoro la variante 
p.R3903Q è stata identificata in omozigosi in un paziente affetto da MmD, in accordo 
con la trasmissione autosomica recessiva della patologia. Cinque varianti 
[c.7112A>G (p.E2371G), c.7035C>A (p.S2345R), c.7355G>C (p.A2452P), 
c.9293T>A (p.S3098I) and c.13990T>C (p.C4664R)] sono nuove varianti di 
sequenza. Infine, in un paziente affetto da CCD oltre alla variante missense p.S3098I 
è stata identificata anche la variante-inserzione p.F4924_V4925insRQGVALLPFF. 
Tale variante consiste in un’inserzione in frame di 30 nucleotidi nell’esone 102  e 
determina a livello proteico l’inserzione 10 aminoacidi nel dominio transmembrana 
M10 della regione C-terminale di RYR1. La regione C-terminale transmembrana di 
RYR1 contiene le sequenze che formano il  poro, siti di legame per la rianodina, siti 
multipli di inattivazione del canale ed è fondamentale anche per l’organizzazione 
tetramerica del canale RYR1. In particolare l’inserzione mutazione cade in un’ α –
elica adiacente la putativa regione che forma il poro del canale. Gli studi di 
predizione della struttura secondaria, attraverso il programma Emboss’ Garnier, e 
l’analisi del profilo di idropatia, attraverso il programma Octanol, mostano che 
l’inserzione p.F4924_V4925insRQGVALLPFF interrompe l’organizzazione strutturale 
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ad elica e modifica il profilo di idropatia  del dominio M10 del canale RYR1 mutato. 
Inoltre, lo studio delle sequenze adiacenti l’inserzione ha dimostrato che la sequenza 
inserita corrisponde ad una porzione dell’introne 105 dello stesso gene RYR1, 
inserita in senso inverso. Per studiare il possibile meccanismo molecolare coinvolto 
in questa alterazione nucleotidica, è stato eseguito il sequenziamento dell’intera 
regione genomica dall’introne 102 all’esone 106 del gene RYR1. E’ stato escluso che 
l’inserzione fosse dovuta a un evento di trasposizione conservativa in quanto la 
sequenza dell’introne 105 è conservata. Pertanto, è possibile ipotizzare un evento di 
trasposizione replicativa come meccanismo responsabile della variante-inserzione. 
La discriminazione allelica, eseguita mediante una long range PCR con un 
oligonucleotide allele specifico, ha dimostrato che la variante di sequenza p.S3098I e 
la variante-inserzione sono presenti sullo stesso allele. Inoltre, attraverso studi di 
espressione è stato dimostrato che nel paziente affetto da CCD la doppia variante 
nel gene RYR1 genera un mRNA instabile; infatti, l’espressione dell’allele RYR1 
mutato rappresenta circa il 16% di quella dell’allele wild tipe. Inoltre, lo studio dei 
livelli di espressione di ciascun allele RYR1 del paziente affetto da CCD ha mostrato 
che l’espressione dell’allele wild type rappresenta circa il 76% del controllo e quella 
dell’allele mutato il 13%, quindi i livelli totali di mRNA di RYR1 nel paziente affetto da 
CCD sono circa l’89% rispetto al controllo.  
Nove varianti di sequenza sono state caratterizzate funzionalmente mediante saggi 
in vitro, in linfociti B immortalizzati con EBV provenienti dai soggetti portatori di tali 
varianti. L’utilizzo dei linfociti B come sistema cellulare consente di studiare l’attività 
del canale RYR1 isolato dalle proteine normalmente presenti nel muscolo sheletrico 
che ne modulano la funzionalità. In particolare, sette varianti di sequenza sono state 
studiate attraverso un saggio metabolico che misura la risposta cellulare dei linfociti 
B alle stimolazioni chimiche come rilascio protonico nell'ambiente extracellulare. Le 
risposte metaboliche alle stimolazioni con il 4-cloro-m-cresolo (4-CmC, un attivatore 
di RYR1) dei linfociti B portatori delle varianti di sequenza localizzate nelle regioni N-
terminale e centrale del canale RYR1 (p.R530H, p.R2163P, p.N2342S, p.S2345R, 
p.E2371G, p.R2454H) sono significativamente più elevate rispetto a quelle delle 
linee cellulari di controllo. L’iper-reattività dei canali RYR1 mutati alle stimolazioni con 
il 4-CmC spiega il fenotipo MHS dei soggetti in cui sono state identificate tali varianti. 
Invece, la velocità di rilascio protonico in risposta alle stimolazioni con il 4-CmC è 
significativamente ridotta nei linfociti B portatori della variante p.C4664R, localizzata 
nella regione C-terminale della proteina, rispetto al controllo. In letteratura è riportato 
che mutazioni localizzate nella porzione C-terminale di RYR1 conferiscono ai canali 
ipo-reattività alle stimolazioni chimiche. I canali RYR1 con queste mutazioni sono 
definiti canali leaky perchè liberano Ca2+ anche in assenza di stimolazione per cui i 
depositi dell’ ER sono ridotti e liberano minori quantità di Ca2+ in seguito a 
stimolazione di RYR1. Per verificare se la mutazione p.C4664R conferisce al canale 
un carattere leaky è stata misurata la quantità di Ca2+ presente come deposito nel 
ER. Le risposte metaboliche registrate nei linfociti B portatori della variante 
p.C4664R in risposta al trattamento con la tapsigargina (TG), un inibitore delle 
pompe del Ca2+ del SR/ER, sono risultate ridotte di circa il 50% rispetto al controllo. 
Questo dato indica che i depositi di Ca2+ nel ER delle cellule che esprimono la 
variante di sequenza C4664R sono ridotti.  I saggi citfluorimetrici di rilascio di calcio 
in risposta alla TG eseguiti sui linfociti che esprimono la variante p.C4664R hanno 
confermato il carattere leaky dei canali mutati. Infatti la quantità di Ca2+ rilasciata dai 
linfociti che esprimono questa variante in seguito alle stimolazioni sia con il 4-CmC 
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sia con la TG è significativamente ridotta rispetto al controllo.  Infine, l’alterata 
funzionalità dei canali RYR1 che esprimono la doppia variante di sequenza 
p.S3098I/F4924_V4925insRQGVALLPFF è stata dimostrata attraverso i saggi 
citofluorimetrici di rilascio di calcio; i linfociti che esprimono i canali mutati, estratti dal 
paziente affetto da CCD e immortalizzati, mostrano un aumento significativo del 
rilascio di calcio, in seguito a stimolazione con 4-CmC, rispetto ai linfociti controllo. 
I risultati ottenuti in questo lavoro di tesi, in parte pubblicati su Human Mutation 
(2009), contribuiscono ad arricchire le conoscenze sulle basi molecolari delle 
malattie genetiche associate a mutazioni del gene RYR1 e sulle loro diverse 
caratteristiche fisiopatologiche. Inoltre, lo studio dell'influenza di una determinata 
mutazione sulla struttura e funzione della proteina potrebbe fornire un considerevole 
contributo alla diagnosi. Infatti, le linee guida per l'analisi molecolare genetica della 
suscettibilità all'MH indicano che una mutazione del gene RYR1 può essere 
considerata causativa di MH solo quando è stato dimostrato, mediante saggi in vitro, 
che essa altera le proprietà di rilascio del calcio del canale RYR1. Pertanto, un 
individuo che ha una mutazione causativa può essere considerato MHS sulla sola 
base dei dati biomolecolari, anche in assenza del risultato dell’IVCT. Quindi, in questi 
casi, l'analisi genetica dà risultati diagnostici conclusivi e il vantaggio per le famiglie 
MH, specialmente per grandi famiglie o quando i parenti rifiutano di sottoporsi a 
biopsia muscolare, appare evidente. Inoltre, l'analisi genetica può fornire anche 
ulteriori dati alla diagnosi strumentale. Infatti, sebbene l'IVCT sia il test di riferimento 
per l'MH, sono stati identificati rari casi di discordanza tra genotipo, caratterizzato 
dalla presenza di una mutazione causativa, e fenotipo, tipizzato MHN mediante 
IVCT. Sulla base di queste osservazioni è stato proposto che tali soggetti, in quanto 
portatori di una mutazione causativa, debbano essere considerati MHS ai fini clinici. 
Quindi l'analisi genetica permette di individuare questi rari ma pericolosi casi di falsi 
negativi e può contribuire alla definizione della sensibilità diagnostica dell'IVCT. 
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1. INTRODUCTION 
 
 
1.1 Ryanodine receptor 1 (RYR1) 
 
RYR1 is the skeletal isoform of the ryanodine receptors (RYRs), intracellular ligand-
gated Ca2+ release channels. RYRs are large homo-tetrameric proteins (molecular 
weight of 2.26 MDa) present in the sarco/endoplasmic reticulum (SR/ER) 
membranes, an intracellular calcium storage organelle. RYRs are involved in the 
control of Ca2+ homeostasis by releasing calcium ions from intracellular stores into 
the cytoplasm [Fill et al., 2002]. Three mammalian isoforms have been identified and 
named according to the tissue where they were first identified:  
§ the skeletal ryanodine receptor, or type 1 (RYR1), the predominant isoform in 
skeletal muscle [Zorzato et al., 1990], but also expressed in the lymphocyte 
cells [Sei et al., 1999]; 
§ the cardiac ryanodine receptor, or type 2 (RYR2), the most abundant isoform 
in cardiac muscle [Nakai et al., 1990], also present in the cerebellum; 
§ the ryanodine receptor 3 (RYR3), expressed in many tissues but originally 
purified from the brain [Hakamata et al., 1992].  
RYRs are encoded by three different genes located on human chromosomes 
19q13.1 (RYR1), 1q42.1-q43 (RYR2) and 15q14-q15 (RYR3) [Sorrentino et al., 1993; 
Otsu et al., 1990; Philips et al., 1996]. At the amino acid level, the three mammalian 
isoforms share about 70% sequence identity [Rossi and Sorrentino, 2002]. 
 
 
1.1.1 Stucture and topology 
 
The RYR1 is encoded by the RYR1 gene, a large gene organized in 106 exons. 
RYR1 is made up of four 565-kD subunits which form a Ca2+ channel of  SR/ER. 
Each subunit is organized into two principal regions, a transmembrane (TM) region 
and a cytoplasmic (CY) region. Membrane-spanning portions of each subunit form an 
ion-conducting pore, whereas the CY region regulates gating via interaction with a 
variety of intracellular messengers. The C-terminal region is on the SR/ER lumen 
side and contains the hydrophobic pore-forming region, while the remaining 70–80% 
of the molecule has been assigned to the SR/ER cytoplasmic side and forms a large 
hydrophilic region, called “foot region”, that contains most ligand binding sites [Sutko 
et al., 1996]. The topology of the C-terminal region has not yet been elucidated. 
Depending on the model, the exact number of transmembrane (TM) domain ranges 
between 4 and 12. Primary sequence and hydropathy plot analysis by Takeshima et 
al. [1989] suggest an arrangement of four transmembrane spanning α-helices (M1 
corrisponding to the amino acids F4564-Y4580, M2 to P4641-L4664, M3 to Q4836-
F4859, and M4 to I4918-I4937) and a final tail facing the SR/ER lumen. In a second 
model, Zorzato et al. [1990] proposed 12 transmembrane domains: MI (G3124-
F3144) and MII (P3188-L3206), both considered to be tentative, and M1 (L3985-
A4004), M2 (M4023-A4041), M3 (G4277-A4300), M4 (A4342-F4362), M5 (F4559-
Y4580), M6 (L4648-F4671), M7 (F4789-V4820), M8 (L4837-F4856), M9 (M4879-
G4898), and M10 (V4914-I4937). M1–M4 in the Takeshima model correspond to M5, 
M6, M8, and M10 in the Zorzato model. More recently, Du et al. [2002] demonstrated 
that the MI, MII, M1, M2, and M3 sequences are not membrane-associated. In the Du 
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model, RYR1 contains eight transmembrane helices and M9 is not a transmembrane 
helix, but it might form a selectivity filter between M8 and M10 (Fig. 1). 
 
 
 
Fig. 1 Transmembrane topology of rabbit skeletal muscle RYR1 [Du model, Du et al., 2002]. The first 
two cylinders with dashed lines indicate the tentative nature of the composition of the first predicted 
helical hairpin loop (M3–M4 or M4a–M4b) in the transmembrane sector of RYR1. The numbers, M3–
M10, inside each transmembrane sequence are those proposed in the Zorzato model [Zorzato et al., 
1990]. The long M7 sequence of the Zorzato model is designated as M7a and M7b. The proposed 
selectivity filter between M8 and M10 is designated as (M9) and is clearly not a transmembrane 
sequence (figure from Du et al., 2002). The structure of RYR1 in a closed conformation was 
determined to 9.6 Å resolution by using cryo-electron microscopy (cryoEM) and computer 
reconstruction techniques. In the CY region of each RYR1 monomer, 36 α-helices and 7 β-sheets can 
be resolved (Fig. 2). Several α-helices with various inclination angles to the membrane plane are 
found in the stem region and could be involved in maintaining the connection between the membrane-
spanning and the cytoplasmic regions [Serysheva et al., 2008]. 
 
 
 
 
Fig. 2 A. 9.6 Å resolution 3D map of RYR1 in its closed conformation is shown in a side view. CY and 
TM regions are indicated. Segmented individual RYR1 subunits are shown in different colors. The 
map is displayed at the threshold level corresponding to channel molecular mass of about 2.3 MDa. B. 
Two opposing RYR1 subunits from the channel tetramer are displayed as semi-transparent surfaces. 
36 α-helices are annotated as cylinders colored according to their locations in the map. 7 β-sheets are 
shown as yellow surfaces (figure from Serysheva et al., 2008).  
 
 
An atomistic model of the pore-forming region of the tetrameric RYR1 was presented 
by Ramachandran et al., [2009]. Figure 3 A shows two of the four inner helices and 
pore helices connected by a long luminal loop. Site-directed mutagenesis [Gao et al., 
2000] predicts that RYR1 has a selectivity filter (4894GGGIGD) (Fig. 3 B), which is 
analogous to K+ channels [Ludtke et al., 2005]. In fact, mutations in the 4894–4899 
sequence of RYR1 alter the conductance of the channel, supporting the assignment 
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of this sequence as the selectivity filter. Both the cytoplasmic and luminal faces of the 
pore are highly negatively charged (as seen in the surface representation in Fig. 3C 
and 3D), which may allow cations to concentrate around the mouths of the pore. The 
model exhibits structural similarities with the K+ channel MthK, such as the 
positioning of the pore helix and the inner helix and the bending of the inner helix, 
although in RYR1 the pore is significantly wider [Ramachandran et al., 2009]. 
 
 
 
 
Fig. 3 The pore model. A. Two opposing RYR1 monomers shown in cartoon representation. The 
selectivity filter (the motif 4894GGGIGDE) is shown in yellow. B. Selectivity filter region of two 
opposing RYR1 monomers shown in stick representation. The sequence of the fragment is shown 
along the path of the ions. The molecular surface of the luminal face (C) and the cytoplasmic face (D) 
of RYR1 pore tetramer. Negative residues are shown in red while positive residues are shown in blue 
and the neutral residues are shown in white (figure from Ramachandran et al., 2009). 
 
 
1.1.2 Gating of RYR1 
 
Cryo-electron microscopy (cryoEM) and single-particle image analysis of frozen-
hydrated RYR1 revealed the 3D structure of RYR1 at approximately 25–30 Å 
resolution [Serysheva et al., 1995; Radermacher et al., 1994; Wagenknecht and 
Samsò, 2002]. The cytoplasmic domain is shaped like a flat square prism of 290 Å 
side and 120 Å high, with at least 12 reproducible domains that have been assigned 
numerals 1–12 [Samsò et al., 2005]. Recently, Samsò et al., [2009] demonstrated 
that the ion pathway of RYR1 is formed by two sets of bundles, each containing four 
rods along a common axis. One set (inner helices) stretches from the lumen to the 
ion gate, whereas the second (inner branches) stretches from the ion gate to the 
peripheral cytoplasmic domains. The configuration of the two bundles is clearly 
different in the two physiological states (closed and open), allowing a 4 Å increase in 
diameter of the ion gate upon opening. This diameter increase is sufficient to ensure 
flow of calcium ions. Upon gating, the cytoplasmic domains undergo a conformational 
change that converges on the inner branches, revealing a long-range allosteric 
mechanism that directly connects effectors acting on the cytoplasmic moiety with the 
ion gate. Samsò et al., [2009] proposed that three structures, the inner branches, the 
inner helices, and horizontal rod-like structure (h1) densities, by forming a mobile 
axial structure, are the three main gating effectors (Fig. 4). In the closed state (Fig. 4 
A), the two right-handed bundles (inner helices, inner branches) form the high-
density constriction (ion gate) at their meeting point. In going from the closed to the 
open state, both sets of bundles relax and appear to contribute equally to lowering 
the density of the ion gate (see arrows in Fig. 4 A). The h1 densities also contribute 
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to the constricting effect in the closed state and move outwards as the gate opens. In 
the closed state, the inner helices form a right-handed helical bundle constricting 
towards the cytoplasm (Fig. 4 A). A slight decrease in density in the region closest to 
the cytoplasmic side of the membrane indicates a point of flexibility. In the open 
conformation (Fig. 4 B), the bottom halves of the inner helices (proximal to the 
lumen) are reoriented in four ways with respect to the closed state. They are shifted 3 
Å along the 4-fold axis towards the cytosol, they are in a more vertical position with 
respect to the 4-fold axis causing the portion facing the ion gate to move farther away 
from each other, and they are slightly bent outwards (Fig. 4 B). After this bend, the 
electron density of the inner helices becomes very weak. The inner helices clearly 
point to a ring of density that has a larger diameter and is less thick in the open state 
than in the closed state (Fig. 4 A and 4 B). These data confirm that this ring of 
density is the ion gate. The outward movement of the h1 densities is concomitant 
with the outward and upward (toward the cytoplasm) movement of the inner helices 
upon opening (arrows in Fig. 4 A), which accounts for the slightly wider and shorter 
appearance of the transmembrane domain in the open state. 
 
 
 
Fig. 4 Stereo view of RYR1 in the closed and open states. Side view of RYR1 in the closed (A) and 
open (B) states, respectively, with the region indicated with a square magnified. The two bundles 
formed by the inner branches and the inner helices define the ion gate at their meeting point. A. The 
arrows indicate how the different structures move upon opening. B. The arrows indicate the pathway 
of the ion flow. The identifiable features are indicated, and the abbreviations are as follows: cytosolic 
constriction (cyt constriction), horizontal rod-like structures (h1, h2), possible continuation of the inner 
helices (i’), and putative selectivity filter (putative sel filter). The gray dashed lines indicate the 
approximate boundary of the SR membrane. Scale bar indicates 10 Å (figure modified from Samsò et 
al., 2009). 
 
 
The inner branches become bulkier approximately 25 Å away from the ion gate, and 
in the closed conformation, they contact each other forming a 10 Å -diameter ring, 
that represents the cytosolic constriction (Fig. 4). The cytosolic constriction is situated 
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after the putative ion gate and it does not appear to have a direct role in gating. 
However, it is conceivable that the cytosolic constriction has a role in stabilizing the 
closed conformation. The inner branches are probably formed by part of the 4938-
5037 C-terminal sequence downstream of the inner helices since one of the 
predicted α helical segments of this region (Fig. 5) has an estimated length of 21 
residues, which is compatible with its physical measurements of 25 Å [Samsò et al., 
2009]. 
 
 
 
Fig. 5  Secondary Structure Prediction. Predicted regions of hydropathy (dashed line) and a helix 
(continuous line) for the C-terminal region of RYR1. The position of the selectivity (sel) filter is also 
indicated. The G residues (highlighted in gray) are possible points of flexibility (figure from Samsò et 
al., 2009). 
 
Through the mechanism to open and close the ion gate, RYR1 mediates the Ca2+ 
release from SR stores into the cytoplasm during muscle contraction.  
 
 
1.2 RYR1 in excitation-contraction (E-C) coupling  
 
Skeletal muscles are made up of individual components known as muscle fibers (Fig. 
6). Each muscle fiber is delimited by the plasma membrane (sarcolemma) that 
through tubular invaginations called transverse tubules (T-tubules) propagates action 
potentials in the muscle fiber. Muscle fibers are in turn composed of numerous 
smaller myofibrils which make up the contractile element. Myofibrils are divided into 
repeating functional units, the sarcomeres. This repeating pattern gives skeletal 
muscle its striated appearance. A system of membranous sacs, called SR, surrounds 
the myofibrils.  
 
 
Fig. 6 Illustration of the structure of a skeletal muscle. 
 
The action potential generated by the central nervous system propagates to the 
motorneuron innervating the muscle cell. At the neuromuscular junction, the 
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presynaptic terminal nerve releases the transmitter acetylcholine (ACh). ACh diffuses 
across the synaptic cleft and binds to nicotinic receptors localized on the 
sarcolemma, opening the voltage-gated Nav1.4 channels, which elicit a Na+ inward 
current with rapid activation kinetics (Fig. 7). Repolarization of the membrane by fast 
Na+ channel inactivation is supported by opening of delayed rectifier K+ channels that 
mediate an outward K+ current. Buffering of after potentials is achieved by a high Cl– 
conductance near the resting potential, resulting from the Cl– channel ClC-1 
[Lehmann-Horn et al., 1999]. At specialized junctions in the transverse tubular 
system, the signal is transmitted from the tubular membrane to the SR, causing the 
release of Ca2+ ions into the myoplasm, which activate the contractile apparatus 
[Leong et al., 1998]. This process is called E-C coupling, which transform electrical 
signals into mechanical signal. The combination of one T-tubule and two adjacent 
terminal cisternae of SR defines a triad, the anatomical site for E-C coupling. Two 
Ca2+ channel complexes are chiefly involved in this process: the ligand-gated homo-
tetrameric RYR1, present in the terminal cisternae of SR, and the voltage-gated 
hetero-pentameric Cav 1 (also called the dihydropyridine (DHP) receptor, DHPR), 
present in the T-tubule membranes. Cav 1.1 senses the membrane depolarization, 
alters its conformation, and activates RYR1, which releases Ca2+ from the SR. Ca2+ 
binds to troponin C and allows myosin and actin to form cross-bridges leading to the 
sliding of actin and myosin filaments with respect to each other and the shortening of 
the sarcomere. The result is muscle contraction [Jurkat-Rott and Frank Lehmann-
Horn, 2005]. 
 
 
 
 
 
1.3 Modulation of RYR1 activity  
 
The RYR1 channels are modulated by several proteins ( e.g., Cav 1.1, calmodulin, 
FKBP12, calsequestrin, triadin, junctin and other proteins), numerous endogenous 
(e.g., Ca2+, ATP, and Mg2+, redox modifications, and phosphorylation) and 
exogenous (e.g., ryanodine, caffeine, local anesthetics, volatile anesthetics, 4- 
chloro-m-cresol, ruthenium red, and dantrolene) modulators [Fill et al., 2002; Sutko et 
al., 1997; Zucchi and Ronca-Testoni., 1997].  
Fig. 7 E-C coupling of skeletal muscle. 
Depolarization of the T-tubule 
membrane activates Cav1.1, triggering 
SR Ca2+ release through RYR1 and 
leading to sarcomere contraction 
(figure from Jurkat-Rott and Frank 
Lehmann-Horn, 2005). 
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1.3.1 RYR1 and regulatory proteins 
 
Cav 1.1 channel is the skeletal isoform of the L-type calcium channel alpha subunit 
Cav 1 and can function both as a voltage sensor and a calcium channel by 
responding to variation in membrane potential. The several isoform are classified on 
the basis of α1 subunit, e.g. α1s  and α1c are skeletal and cardiac isoform in the Cav 
1.1 and Cav 1.2 channels, respectively. Cav 1.1 is a large heteropentamer (435 kDa) 
containing several subunits: α1s (175-212 kDa), α2 (140 kDa), β (55 kDa), γ (33 kDa) 
subunits and the small δ (24-33 kDa) polypeptide chain connected to α2. The α2, β, γ 
and δ subunits have regulatory functions, whereas the α1s subunit  contains the 
voltage sensor, the DHP-binding sites and the pore-forming region. The α1s subunit, 
encoded by CACNA1S gene, consists of 4 highly homologous domains, (I-IV), each 
containing six transmembrane segments (S1-S6) arranged in α-helices (Fig. 8).  
 
 
Fig. 8 Structure of voltage-gated Ca2+ channel Cav 1.1 (figure from Jurkat-Rott and Frank Lehmann-
Horn, 2005). 
 
S4 is positively charged, while the others are hydrophobic. S4 fragment is the 
voltage-sensor, while the regions between the II-III loop are crucial for E-C coupling 
[Jurkat-Rott and Frank Lehmann-Horn, 2005]. Bannister et al., [2008] demonstrated 
that the regions between the III-IV loop are not directly involved in E-C coupling but 
influence Cav 1.1 gating transitions important both for E-C coupling and activation of 
L-type conductance. 
In skeletal muscle (Fig. 9 B), the T tubule contains the Cav 1.1 channels arranged in 
clusters of four (tetrads). RYR1 channel is physically coupled with a Cav 1.1 tetrad. 
The T-tubule membrane depolarization alters the Cav 1.1 conformation. A specific 
cytosolic loop of the Cav 1.1 is involved in a physical communication with RYR1. As 
a consequence, the coupling between Cav 1.1 and RYR1 is bidirectional: an 
orthograde signal from the Cav 1.1 to the RYR1 occurs when depolarisation of the 
membrane triggers a conformational change of α1s subunit of Cav 1.1 and is 
translated into the opening of RYR1 and generation of a retrograde signal from RYR1 
to the Cav 1.1. In cardiac muscle (Fig. 9 B), there is about one Cav 1.2 for every five-
ten RYR2 channels, and the Cav 1.2 and RYR2 channels are not aligned in such a 
highly ordered fashion. The T-tubule membrane depolarization activates the Cav 1.2, 
and the resulting Ca2+ entry triggers underlying RYR2 channels to open and release 
Ca2+  from the SR. This process is named calcium-induced calcium release (CICR) 
[Fill et al., 2002].  
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Fig. 9 Environment of the ryanodine receptor channel in skeletal (A) and cardiac (B) muscle (figure 
from Fill et al., 2002). 
 
 
Calmodulin (CaM) is a small cytoplasmic Ca2+ binding protein that is comprised of 
two globular domains separated by a central α helical domain. Each of the N and C-
terminal domains contains two EF-hand Ca2+ binding sites [Zhang et al., 1995]. The 
two Ca2+ binding sites in the C-lobe have a higher Ca2+ affinity than the two sites in 
the N-lobe, resulting in nearly full occupancy at 100 µM Ca2+ and little binding at 
<0.01 µM free Ca2+. CaM modulates channel activity in response to changing Ca2+ 
intracellular concentrations, binding to the RYR1 with a stoichiometry of four per 
channel tetramer. CaM has a bimodal action on channel activity depending on its 
association with Ca2+ [Samsò et al., 2002].  The Ca2+ bound form (CaCaM, in 
micromolar Ca2+ concentrations) inhibits RYR1 in the absence of ATP, whereas at 
low Ca2+ concentrations (ApoCaM, in submicromolar Ca2+ concentrations) activates 
RYR1. RYR1 proteolysis and mutagenesis experiments have identified a single CaM-
binding domain in the RYR1 channel, corresponding to the amino acid residues 
3614–3643, that interacts with both the Ca2+-free (apoCaM) and Ca2+-bound 
(CaCaM) forms of CaM. [Moore et. al., 1999]. Moreover, synthetic peptides 
corresponding to this region were drawn to bind both apo-CaM and CaCaM 
[Yamaguchi et al., 2001]. Recently, Cornea et al., [2009] investigated Ca2+-
dependent rearrangements of CaM bound to the RYR1 channel by using 
fluorescence resonance energy transfer (FRET). Small FRET acceptors were 
covalently attached to single cysteine residues introduced into N lobe of the CaM, 
central linker, or C lobe. The targeting of FRET donors was a single-cysteine 
fluorescent labeled of FKBP12 (see next paragraph). Cornea et al., [2009] suggested 
new insights into the location and orientation of CaM on the RYR1 channel when 
considered in context with existing structural models. In figure 10 A is shown a recent 
cryo-EM model of the RYR1 [Serysheva et al., 2008] and the atomic model of 
CaCaM in complex with the RYR13614–3640 target [Maximciuc et al., 2006]. In figure 10 
B is shown a space-filling representation of the CaM-RYR13614–3640 complex, as 
indicated by cryo-EM mapping of CaCaM [Wagenknecht et al., 1997; Samsò et al., 
2002]. The placement of CaM in figure 10 B is consistent with the position of CaCaM 
in RYR1 cryo-EM models [Wagenknecht et al., 1997]. In the Cornea model, the 
domain of CaM nearest to FKBP12 and adjacent to the handle region is identified as 
the N lobe, whereas the C lobe is placed beneath the clamp region. This model thus 
positions N and C lobe of CaM Ca2+-binding sites within distinct microdomains of the 
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channel. The location of the RYR13614–3643 target helix within the domain structure of 
the channel is not defined in existing structural models. In this model, the target helix 
is placed near the outer edge of domain 3 (Fig. 10 A). Alternatively, the target helix 
may also lie along the edge of domain 8 without significantly changing distance 
relationships between CaM and FKBP. 
 
 
 
Fig. 10 Suggested placement of CaM within the RYR1 3D architecture. A. Left The RYR1 cryo-EM 
structure is shown in side view. (Scale bar: 100 Å.) The dashed red circle indicates the FKBP12-
binding site, and the red dot approximates the predicted position of donor fluorophore attachment 
based on the model of Samsò et al. [2002]. The dashed blue oval approximates the site of CaCaM 
binding within the cleft separating cytoplasmic domains 3 and 8. Right Atomic structure of CaCaM in 
complex with RYR13614–3640. Positions of acceptor attachment within  N lobe and C lobe of CaM are 
highlighted in red (labeling site within the central linker is obscured). B. Proposed placement of CaM. 
A space-filling representation of CaM–RYR13614–3640 is positioned within the channel cleft and oriented 
such that the N lobe is nearest and C lobe farthest from FKBP12, as indicated by FRET (figure from 
Cornea et al., 2009). 
 
FKBP12 is the 12 kDa FK506-binding protein, a cytosolic receptor for the 
immunosuppressant drugs FK506 and rapamycin, that constitutively binds to the 
RYR1. Removal of FKBP12 using FK506 or rapamycin causes an increased open 
probability and an increase in the frequency of sub-conductance states in RYR1. 
FKBP12 facilitates the coordination of channel opening to full conductance [Brillantes 
et al., 1994]. Binding sites for FKBP12 have been localised by cryo EM and this 
approach has yielded a model of four symmetrically related binding sites about 10 
nm apart from the cytoplasmic assembly of the RYR1 [Wagenknecht et al., 1996]. 
Q3, R18 (N-terminal regions), and M49 residues of FKBP12 are essential and unique 
for binding of FKBP12 to RYR1 in skeletal muscle [Lee et al., 2006]. Using cryo EM 
and single-particle image processing, also Samsò et al., [2006] have determined that 
N-terminal region (Q3 residue) of FKBP12 participates directly in the interaction with 
RYR1. The orientation of RYR1-bound FKBP12, with part of its FK506 binding site 
facing towards RYR1, suggests how FK506 is involved in the dissociation of FKBP12 
from RYR1. 
 
Calsequestrin, triadin and junctin. Calsequestrin (CSQ) is the major Ca2+-binding 
protein in the lumen of the SR where it forms a linear polymer closely associated with 
the junctional face membrane [Franzini-Armstrong et al., 1987]. The inhibiting action 
of CSQ on the RYR1 channel depends on the presence of triadin and junctin [Gyorke 
et al., 2004] both transmembrane SR proteins which bind to CSQ and the RYR1 
forming a quaternary complex (Fig. 11).  
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CSQ is highly acidic and contains up to 50 Ca2+-binding sites, which are formed 
simply by clustering of two or more acidic residues. The protein polymerises when 
Ca2+ concentrations approach 1mM. CSQ was considered the main candidate for a 
luminal Ca2+ concentration-detector because Ca2+ stabilizes CSQ conformation and 
the CSQ polymer [Wang et al., 1998]. The response of RYR1 channels to a 
decreased luminal Ca2+ concentration differs in the presence/absence of the CSQ, 
and thus provides evidence that CSQ is a dominant luminal Ca2+ sensor for the 
RYR1. Recently Qin et al., [2009] demonstrated that no significant luminal Ca2+- 
sensitivity of RYR1 was detected in the presence of CSQ added to the luminal side of 
single RYR1 channels over the physiologically relevant range (0.05-1 mM Ca2+). 
These results indicate that CSQ-dependent luminal Ca2+ regulation in skeletal muscle 
likely plays a relatively minor role in regulating the RyR1 channel activity and that the 
main role of CSQ1 in this tissue is as an intra-SR Ca2+ buffer. In contrast, the luminal 
Ca2+ sensitivity of single RYR2 channels was substantial when CSQ was present.  
Triadin was first identified in skeletal muscle as a 95 kDa transmembrane protein 
[Brant et al.,1990] that is abundantly expressed on the junctional SR, where it 
colocalizes with RYR1 and Cav 1.1 and binds to CSQ and the RYR1 [Guo and 
Campbell, 1995]. Shen et al., [2007] indicated an indirect role for triadin in regulating 
myoplasmic Ca2+ homeostasis and organizing the molecular complex of the triad but 
not in regulating skeletal E-C coupling. 
Junctin was later discovered and thought to have a comparable function to triadin, 
due to its similar structure and its ability to also bind CSQ and the RYR1 [Tijskens et 
al., 2003]. A putative triadin binding site was identified in the terminal intraluminal 
loop of RYR1 between amino acid residues 4860 and 4917 [Lee et al., 2004]. Alanine 
substitution of three specific negatively charged residues within this region (D4878, 
D4907, and E4908) was found to disrupt triadin binding to RYR1 [Lee et al., 2006]. 
Goonasekera et al., [2007] demonstrated a single mutation to any of these three 
negatively charged residues is not sufficient to modify RYR1–triadin association and 
the combination of the different mutations indicates that each residue contributes 
unequally (D4907 > E4908> D4878) to triadin to RYR1. This interaction is an 
important regulator of both voltage- and ligand-induced SR Ca2+ release in skeletal 
muscle. They proposed a model where by triadin binding to RYR1 enhances release 
channel opening in response to both voltage- and ligand-induced activation and that 
this activity is important for ensuring robust and rapid calcium release during E-C 
coupling. 
 
Fig. 11 The quaternary complex: 
CSQ–triadin (TRI)–RYR1–junction 
(JUN) [figure from Goonasekera  et al., 
2007]. 
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Other proteins interact with the RYR1: sarcoplasmic reticulum protein 35 (SRP35) 
[Zorzato et al., 2009], sarcoplasmic reticulum protein 27 (SRP27) [Bleunven et al., 
2008], JP-45 [Anderson et al., 2003], sorcin [Meyers et al., 1995], S-100 [Treves et 
al., 1997], mistugumin-29 [Takeshima et al., 1998], junctate [Treves et al., 2000], 
junctophilin [Takeshima et al., 2000], homer [Feng et al., 2002]. Some proteins, JP-
45, SRP27, SRP35, and junctate, are components of the EC-coupling machinery. JP-
45 is mainly expressed in skeletal muscle, down regulated during ageing and a 
component interacting with the subunit of αs of Cav 1.1 and CSQ. JP-45 appears to 
be important for the functional expression of the Cav 1.1. 
 
 
1.3.2 Endogenous modulators of  RYR1 
 
Calcium. RYR1 channels are activated by low Ca2+ concentrations (1–10 µM) and 
inhibited by high Ca2+ concentrations (1–10 mM). Trypsin digestion of the luminal 
side of the RYR1 channel suggested the presence of both activating and inactivating 
divalent sites [Ching et al., 2000]. Ca2+ release studies suggested that Ca2+ binding to 
the luminal surface of the RYR1 channel may regulate the channel [Donoso et al., 
1996; Donoso et al., 1995]. Sensitivity of RYR1 channel to certain cytosolic agonists 
increases at high luminal Ca2+ levels [Gyorke I and Gyorke S 1998]. Probably, the 
luminal Ca2+ effects are mediated by associated proteins like calsequestrin [Beard et 
al., 2002] or junctin [Zhang et al., 2001].  
 
ATP and Mg2+. Cytosolic ATP and Mg2+ are an effective RYR1 channel activator and 
inhibitor, respectively. The cytosol of most cells contains ~5 mM total ATP and ~1 
mM free Mg2+. The action of ATP and Mg2+ on single RYR channel function is isoform 
specific. Free ATP is a much more effective activator of the RYR1 channel than of 
the RYR2 channel [Copello et al., 2002], and of the RYR3 channel [Chen et al., 
1997]. Mg2+ may compete with Ca2+ at the Ca2+ activation site, shifting the Ca2+ 
sensitivity of the channel. Moreover, Mg2+ competes with Ca2+ at the high Ca2+ 
inhibition site. The high Ca2+ inhibition site does not discriminate between different 
divalent cations. In the presence of physiological levels of Mg2+ and ATP, the RYR1 
channel requires less Ca2+ to activate than the RYR2 or RYR3 channel [Copello et 
al., 2002]. 
 
Redox modifications. Reactive oxygen species and nitric oxide (NO) derivatives are 
synthesized by skeletal muscle. Reversible redox modifications of RYR1 are S-
nitrosylation, S-glutathionylation, and disulfide oxidation. Each subunit of RYR1 
contains 101 cysteines [Sun et al., 2001 a], but one redox-sensitive cysteine (C3635) 
has been proposed as functionally relevant to the redox sensing properties of the 
channel. C3635 is selectively nitrosylated [Sun et al., 2001 b], and this modification 
regulates the interaction of calmodulin with RYR1 [Oba et al., 2002] and is likely to 
play a modulatory role in voltage-gated E-C coupling. By using mass spectrometry, 
Voss et al., [2004] identified in RYR1 seven hyper-reactive cysteines (C1040, C1303, 
C2436, C2565, C2606, C2611, and C3635) that are thought to be targets for disulfide 
cross-linking, S-nitrosylation, and/or S-glutathionylation. These modifications 
increase channel activity, but appear to do so by different mechanisms. Both S-
nitrosylation and oxidation increase the sensitivity of the channel to Ca2+ activation, 
whereas S-glutathionylation decreases selectively the sensitivity of the channel to 
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inhibition by Mg2+ [Salama et al., 1992] and the response of the channel to 
nitrosylating agents [Xia et al., 2000].  
 
Phosphorylation. The cAMP-dependent protein kinase PKA and the protein 
phosphatase 1 (PP1) regulate the phosphorylation/dephosphorylation of the RYR1 
channel [Marx et al., 2001].  Reiken et al., [2003] identified the S2843 as unique PKA 
phosphorylation site on RYR1 using site directed mutagenesis; this PKA 
phosphorylation site was previously identified by Sutko et al., [1993] using 
phosphopeptide mapping. PKA phosphorylation of RYR1 at S2843 activates the 
channel by releasing FKBP12. Recently, Blayney et al., [2009] studied the interaction 
between RYR1 and FKBP12 by using the experimental inhibitory drug K201, a multi-
channel blocker. They demonstrated that phosphorylation and K201 behave similarly 
to change the conformation of RYR1 and regulate FKBP12 binding. K201 stabilizes 
the closed conformation, whereas phosphorylation facilitates a subsequent molecular 
event that might increase the rate of an open/closed conformational transition. 
  
 
1.3.3 Exogenous modulators of  RYR1 
 
Ryanodine gives the name to receptor that specifically binds, RYR channel. 
Ryanodine is an alkaloid extract from the plant Ryania speciosa. Low doses of 
ryanodine (~10 nM) increase the frequency of single RYR channel openings to the 
normal conductance level [Buck et al., 1992]. Intermediate ryanodine doses (~1 µM) 
induce very-long-duration open events and simultaneously reduces ion conductance 
through the pore. High doses of ryanodine (~100 µM) lock the channel in a closed 
configuration [Zimanyi et al., 1992]. The ryanodine-binding site has been localized to 
the C-terminus of the protein the region of the RYR1 protein thought to contain the 
structural determinants of the pore. Each RYR1 monomer contains one high-affinity 
ryanodine binding site and the additional lower affinity ryanodine binding sites. RYR1 
monomeres are not able to bind ryanodine, but the tetrameric structure is necessary 
for ligand binding. The ryanodine binding changes the effective diameter of the RYR1 
channel pore [Fill et al., 2002].   
 
Caffeine is an activator of RYR1. Caffeine has been shown to activate Ca2+ release 
from SR by increasing the apparent affinity of the Ca2+ activation site for Ca2+. The 
caffeine causes an increase in the open probability of  RYR1 [Rousseau et al. 1988] 
and renders it more sensitive to voltage sensor activation and physiological activators 
such as Ca2+ and ATP [Herrmann-Frank et al. 1999]. 
 
Local anesthetics. Procaine and tetracaine inhibited SR Ca2+ release induced by 
Ca2+ or  caffeine [Garcia and Schneider, 1995]. A similar action has been observed 
with other local anesthetics, such as the tertiary amines etidocaine, bupivacaine, 
prilocaine, lidocaine, and mepivacaine, the quaternary amines QX 572 and QX 314, 
and the neutral anesthetic benzocaine. Local anesthetics show at least two different 
actions. 1) Channel inhibition associated with reduced ryanodine binding. Such 
action, produced by tetracaine and procaine, is likely to be mediated by a high-affinity 
binding site, corresponding to or interacting with the Ca2+ -binding and adenine 
nucleotide binding sites. 2) Voltage-dependent channel blockade, characterized by 
reduced channel conductance. This action occurred with lidocaine, with quaternary 
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amines, and, possibly, with high concentrations of procaine and tetracaine; it was 
associated with increased affinity for ryanodine, and it is supposed to be mediated by 
a lower-affinity site, located close to the conductive pathway. Additional effects 
cannot be excluded. In particular high concentrations of local anesthetics might affect 
SR Ca2+ release by a nonspecific action on membrane permeability. 
 
Volatile anesthetics. In skeletal muscle and cardiac SR preparations, halothane 
increased SR Ca2+ release at gas concentrations ranging from about 0.002% to 3.8% 
(v/v) [Beltran et al., 1996]. The response to halothane was Ca2+ -dependent and pH- 
dependent. At a pH of 7.4, halothane increased the rate of Ca2+ release at all Ca2+ 
concentrations. At a pH of 6.8, no significant Ca2+ release occurred in the absence of 
halothane, at any Ca2+ concentration, and the stimulation produced by halothane was 
Ca2+-independent [Beltran et al., 1996]. The response to halothane was not affected 
by adenine nucleotides, and it was inhibited by ruthenium red [Frazer and Lynch, 
1992]. Similar effects have been observed with isoflurane and enflurane (2.5 to 4%). 
 
4-Chloro-m-cresol (4-CmC) is a clinically relevant activator of RYR1. It is a structural 
analog of phenol and activates RYR1 with an EC50 ~50-200 µM [Zorzato et al., 
1993]. The structural determinants on RYR1 required for 4-CmC activation have 
been localized to a 173 amino acid region between amino acid residues 4007-4180 
[Fessenden et al., 2003]. Jacobson et al., [2006] suggest that the 4-CmC binding site 
on RYR1 contains two critical components: 1) hydrophilic side chains of amino acids 
to stabilize the 1-hydroxyl on 4-CmC via hydrogen binding and/or electrostatic 
interactions and 2) a hydrophobic surface to interact with hydrophobic groups on the 
3, 4, and/or 5-positions on the benzene ring. 
 
Ruthenium red is a polycationic dye with a structure that includes 14 amino groups. 
Ruthenium red has been shown to inhibit SR Ca2+ release. The inhibition was 
incomplete, because a complete block requires the addition of Mg2+. On the basis of 
single-channel results, it has been demonstrated that the binding site is located 
within the transmembrane region of RYR1, probably close to the pore of the channel, 
and that ruthenium red cannot permeate through the open channel [Ma, 1993]. 
 
Dantrolene, a hydantoin derivative, has structural similarities to both hydantoin and 
some local anaesthetics, but has neither anticonvulsant nor anaesthetic properties. In 
skeletal muscle dantrolene inhibits the RYR1-mediated Ca2+ release [Paul-Pletzer et 
al., 2002]. The dantrolene binding site on RYR1 is located at the N-terminal region 
(amino acids 590–609). Dantrolene reduced the maximum rate of Ca2+ release 
without affecting the Ca2+-sensitivity of the process, and its action was much more 
evident in the presence of caffeine and adenine nucleotides than in their absence 
[Zucchi and Ronca-Testoni 1997]. 
 
 
1.4 RYR1-related disease 
 
The RYR1 channel, which is encoded by the RYR1 gene, plays an essential role in 
the sarco/endoplasmic Ca2+ regulation and in the generation of Ca2+ signals that 
triggers muscle contraction. Mutations in the RYR1 gene, resulting in dysfunctions in 
RYR1 channel activity and defects in sarco/endoplasmic Ca2+ regulation, are linked 
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to malignant hyperthermia and to some congenital myopathies among which the 
most common are core myopathies.  
 
 
1.4.1 Malignant hyperthermia (MH)  
 
MH (MIM 145600) is a potentially lethal pharmacogenetic disorder that affects 
genetically predisposed individuals when they are exposed to volatile anesthetics 
(halothane, enflurane, isoflurane, desflurane, sevoflurane) or depolarizing 
neuromuscular myorelaxants (e.g. succinylcholine). Volatile anesthetics trigger a 
sustained release of Ca2+ from the SR that leads to hypermetabolism, muscle rigidity, 
rhabdomyolysis, and death. First reported in 1960 (Denborough and Lovell, 1960), 
MH is a major cause of anaesthetic related deaths in young, fit individuals [Kaus and 
Rockoff, 1994]. MH exhibits an autosomal dominant mode of inheritance in man with 
an estimated frequency varying from 1:15,000 anesthetic administrations in children 
to 1:50,000 anesthetics in adults [Jurkat-Rott et al., 2000]. The actual frequency is 
difficult to establish since many susceptible individuals will never be exposed to the 
anesthetic triggers. Although the mechanism of MH triggering is specific, the resulting 
clinical features are not. Thus, patients with a variety of neuromuscular disorders are 
sporadically reported to have developed one or more of the clinical features of MH 
(such as pyrexia, tachycardia, hypercapnia, and hyperkalemia) in the perioperative 
period. It is important to distinguish such nonspecific problems from MH, because 
different underlying pathophysiological mechanisms are likely to require different 
treatments and have different implications for the anesthetic management of the 
patient and their family. Therefore, except in conditions where SR Ca2+ release is 
specifically sensitized to volatile anesthetics, as in MH, triggering drugs should not be 
absolutely avoided [Klingler et al., 2009]. 
 
Etiology. MH is a skeletal muscle disorder related to sustained release of Ca2+ from 
the SR with increased intracellular Ca2+ levels. The enhanced intracellular calcium 
results in activation of muscle contraction, oxygen consumption, carbon dioxide 
production. The processes of muscle contraction and of reabsorbing this excess Ca2+ 
accumulation, consumes large amounts of ATP and generates the excessive heat 
(hyperthermia) that is the hallmark of the disease. The muscle cell is damaged by the 
depletion of ATP and by the high temperatures, and cellular constituents are  poured 
into the circulation, including potassium, myoglobin, creatine, phosphate and creatine 
kinase. The low ATP concentration causes muscle rigidity, since the presence of 
ATP is normally required to allow muscle relaxation. ATP depletion causes 
association of actin and myosin filaments so that the muscle becomes rigid and 
inextensible. This is really a premature rigor mortis and explains why the rigidity 
persists up to and after death [Furniss, 1971]. The treatment of a MH crisis consists 
in the administration of the skeletal muscle relaxant dantrolene, an inhibitor of Ca2+ 
release from intracellular stores. After its introduction, the mortality of malignant 
hyperthermia decreased from 80% in the 1960s to < 10% today. Dantrolene 
depresses the intrinsic mechanisms of E-C coupling in skeletal muscle by inhibiting 
RYR1-mediated Ca2+ release [Paul-Pletzer et al., 2002].  
 
Diagnosis. The in vitro contracture test (IVCT) is the “gold standard” for diagnosis of 
MH. The European MH Group (EMHG, www.emhg.org) has developed a 
 20 
standardized protocol for the IVCT [European Malignant Hyperpyrexia Group, 1984]. 
Using this assay patients are assigned MH suscettible (MHS), MH normal (MHN) or 
MH equivocal (MHE) according to the in vitro contracture response of viable muscle 
tissue strips following exposure to halothane and to caffeine. An increase in 
contracture of ≥ 0.2 g at a threshold dose of 2 mM caffeine and 2% halothane is 
considered a positive test result (MHS). A MHN diagnosis is obtained when both 
drug-responses are below the threshold. The MHE class includes patients who react 
to only one of triggering agents used in the test. The IVCT involves an invasive open 
muscle biopsy and is carried out only on patients who had an MH episode or on their 
family members. The IVCT exhibits good diagnostic sensitivity (99%) and specificity 
(93.6%) [Ording et al., 1997]. A slightly different protocol for testing MH susceptibility 
was developed by the North America Malignant Hyperthermia Group 
(www.mhaus.org) and is referred as the caffeine-halothane contracture test (CHCT) 
[Larach, 1989]. The test is associated with lower diagnostic specificity (78%) and 
sensitivity (97%) than the European protocol [Larach et al., 1992]. Modifications of 
the EMHG protocol include the use of ryanodine [Bendahan et al. 2004], which binds 
selectively to RYR1 or 4-CmC [Rueffert et al.,  2002], but to date these agents have 
not been included in the standard protocol. Anetseder et al., [2002] proposed a less 
invasive open muscle biopsy in which intramuscular injections of caffeine lead to an 
increase in carbon dioxide pressure only in MHS subjects. At present, the clinical 
approach for MHS subjects involves the use of non-triggering anesthesial agents, 
thus bypassing the need for an extensive preoperative workup. The anesthesia is 
managed with a combination of non-triggering anesthetics (barbiturates, nitric oxide, 
propofol, narcotics) and local anesthetics. On the day of the operation, the patient is 
carefully monitored. If a MH episode occurs, the dantrolene is administrated (2-
2.4mg/kg of body weight) and injection are repeated until symptoms persist (10mg/kg 
is maximal dose).  
 
Genetic basis. Sequence variants of  RYR1 gene have been identified in up to 70% 
of MH families [Klingler et al., 2009]. MHS1 locus (MIM  180901), located on 
chromosome 19q13.1, is a main site where the RYR1 gene maps [McCarthy et al, 
1990]. However, a considerable genetic heterogeneity has been reported for MH; in 
fact, other five MH susceptibility loci have been mapped to specific chromosome 
intervals. The nomenclature of the MHS loci followed the order of their appearance 
(Tab. 1). The MHS2 locus (MIM 154275) has been linked to chromosomal locus 
17q11.3-q24 where the SCN4A gene maps [Levitt et al., 1992]. This gene encodes 
α subunit of voltage-dependent sodium channel expressed in the skeletal muscle. 
The MHS3 locus (MIM 154276), assigned to chromosome 7q21-q22, contains the 
CACNL2A gene that encodes the α2/δ subunit of the calcium channel Cav 1 [Illes et 
al., 1994]. The MHS4 locus (MIM 600467) was mapped to chromosome 3q13.1 and 
a candidate gene was not identified yet [Sudbrak et al., 1995]. The MHS5 locus (MIM 
601887), located on chromosome 1q32, contains the CACNA1S gene that encodes 
the α1S subunit of Cav 1.1. Sequence variants have been identified in this gene in 
Italian, German and French MH families [Pirone et al., 2007; Jurkat-Rott et al., 2000; 
Monnier et al., 1997]. It was estimated that sequence variants in this gene account 
for 1% of all MH cases. Finally, the MHS6 locus (MIM 601888) was located on 
chromosome 5p  [Robinson et al., 1997].  
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Tab. 1 MH susceptibility loci and their chromosomal location. 
 
Thus far, more than 200 sequence variants have been identified in the RYR1 gene, 
the main locus of MH susceptibility [Anderson et al., 2008; von der Hagen et al., 
2008; Monnier et al., 2008; Sato et al., 2008; Kossugue et al., 2007; Lyfenko et al., 
2007; Rossi et al., 2007; Zhou et al., 2007; Robinson et al., 2006]. The majority of 
variants (96%) linked to MH so far detected in the RYR1 gene are missense changes 
[Robinson et al., 2006] and are clustered in three main ‘‘hotspot’’ regions of the 
RYR1 protein: residues 35-614 (region 1), residues 2117-2787 (region 2) and 
residues 4136-4973 (region 3). Almost all mutations occur at the heterozygous state, 
and homozygotes was rarely reported [Lynch et al. 1997].  
 
Genetic testing. According to guidelines of EMHG, mutation analysis of RYR1 gene 
is used in predictive genetic testing of MH susceptibility and is offered to IVCT-
positive patients and their relatives, as well as to patients who suffered from 
suspected MH episodes and their relatives. So far, only 28 sequence variants of 
RYR1 (Tab. 2), investigated for their functional effect, fulfil the criteria to be included 
in the guidelines for molecular genetic detection of MH susceptibility.   
 
Locus Chromosomal location Gene 
MHS1 19q13.1 RYR1 
MHS2 17q11.3-q24 SCN4A 
MHS3 7q21-q22 CACNL2A 
MHS4 3q13.1 Unidentified 
MHS5 1q32 CACNA1S 
MHS6 5p Unidentified 
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Tab. 2 Causative RYR1 gene mutations included in the guidelines for molecular genetic detection of 
MH susceptibility. 
 
The following criteria have been adopted.  
1) Genetic characterization. Each mutation should be characterised at the genetic 
level, including a full description at the DNA and protein level, considering aspects of 
evolutionary conservation and change in charge, polarity or structure introduced by 
the amino acid replacement, co-segregation of the mutation with the disease in at 
least 2 pedigrees, absence of the sequence change from 100 normal chromosomes 
of the same ethnic group for exclusion of polymorphisms.  
2) Functional characterisation. The effect of each mutation on RYR1 function should 
be assayed in the following cell system:  
- assays on HEK293 cells, myotubes of the dyspedic mouse. The standard system is 
based on the expression of a rabbit mutant RYR1 cDNA construct in HEK293 cells. 
Calcium release is measured fluorimetrically in response to triggering agents (Tong 
et al 1997, Lynch et al. 1999, Tong et al. 1999, Monnier et al. 2000, Sambuughin et 
al. 2001, Oyamada et al. 2002). The advantage of the system is the standardised 
genetic background of the recipient cell line. This cell system allows for direct 
comparison between mutations and eliminates the potential influence of mutations in 
other genes which could modify the RYR1 function in cells taken from patients. 
Alternatively, myotubes of the dyspedic mouse (RYR1-knock out) have been used as 
recipients for the expression of cDNA constructs (Avila et al. 2001). In this cell 
system both Ca2+ release and E-C coupling can be studied. Again, cDNA construct 
and genetic background are well defined and standardised. The genetic expression 
EXON NUCLEOTIDE AMINO ACID 
2 c.103T>C p.C35R 
6 c.487C>T p.R163C 
6 c.488G>T p.R163L 
9 c.742G>A p.G248R 
11 c.1021G>A p.G341R 
12 c.1209C>G p.I403M 
14 c.1565A>C p.Y522S 
15 c.1654C>T p.R552W 
17 c.1840C>T p.R614C 
17 c.1841G>T p.R614L 
39 c.6487C>T p.R2163C 
39 c.6488G>A p.R2163H 
39 c.6502G>A p.V2168M 
40 c.6617C>T p.W2206M 
40 c.6617C>G p.W2206R 
44 c.7048G>A p.A2350W 
44 c.7124G>C p.G2375A 
45 c.7282G>A p.A2428W 
45 c.7300G>A p.G2434R 
45 c.7304G>A p.R2435H 
46 c.7360C>T p.R2454C 
46 c.7361G>A p.R2454H 
46 c.7372C>T p.R2458C 
46 c.7373G>A p.R2458H 
100 c.14387A>G p.Y4796C 
101 c.14512C>G p.L4838V 
101 c.14582G>A p.R4861H 
102 c.14693T>C p.I4898W 
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profile of myotubes may be closer to those of  mature muscle. For this reason, results 
may not be directly comparable to the HEK293 cell system. 
- assays on cells derived from patient tissues. Calcium measurements ligand binding 
studies have been performed on tissues from MHS patients (in myotubes [Brinkmeier 
et al. 1999, Wehner et al. 2002], in microsomal SR preparations from muscle 
biopsies [Richter et al. 1997], and in lymphoblasts [Zullo et al., 2009; Girard et al. 
2001, Tilgen et al. 2001]) carrying the RYR1 gene variants. The parameters analyzed 
were Ca2+ release and resting [Ca2+], proton release, ryanodine binding to SR RYR1 
preparations. Moreover, the responses to electrical stimulation can be studied in 
myotubes. Since the tissue were derived from patients, the potential influence of 
other individual genetic factors cannot be excluded. Therefore, in order to remove the 
interference of other genetic factors, the assays should be performed on samples 
from at least two independent patients with the same mutation. 
The study of the impact of a given mutation on the structure and function of the 
protein could have important implications also for MH diagnosis. In fact, according to 
the EMHG guidelines (Urwyler et al., 2001), once a mutation has been detected in 
the proband or index patient, that fulfils the criteria to be included in the guidelines as 
MH causative mutation, it can be used to test relatives who have not yet been tested 
by the IVCT. The individual carrying such a mutation should be regarded as MHS; 
therefore, the genetic analysis may provide conclusive diagnostic information, even 
in the absence of IVCT result. This is useful for large families or if relatives refuse a 
muscle biopsy. However, family members who do not carry the mutation observed in 
the pedigree should still undergo IVCT investigation. The reason for such caution is 
the of discordance between genetic and IVCT results, implicating a second MH 
susceptibility gene segregating in the kinship. Furthermore, genetic analysis may 
also provide adjunctive information to the instrumental diagnosis. Although the IVCT 
is the gold standard test with which to establish the risk for MHS, there have been 
some rare cases of discordance between genotype, characterised by a causative 
mutation, and phenotype, typed MHN by the IVCT [Robinson et al., 2003; Fortunato 
et al., 1999; Brandt et al., 1999; Deufel et al., 1995]. On the basis of these 
observations, it has been proposed that subjects who carry a causative mutation 
should be regarded MHS for clinical purposes [Fortunato et al., 1999]. Therefore, 
genetic analysis will contribute to the definition of the sensitivity of the IVCT, since it 
reveals these rare but nevertheless high-risk cases of subjects falsely typed "normal". 
  
 
1.4.2 Congenital myopathies 
 
Congenital myopathies (CMs) are a heterogeneous group of inherited neuromuscular 
disorders characterized by hypotonia and muscle weakness, that usually present at 
birth or early childhood or rarely adulthood [Goebel, 2005]. The incidence of all 
congenital myopathies is estimated at around 6.0/100.000 live births, or one-tenth of 
all cases of neuromuscular disorders [Wallgren-Pettersson, 1990]. Myopathies linked 
to RYR1 mutations are differentiated on the basis of the histopathological features in: 
- core myopathies (central core disease, multiminicore disease, nemaline rod 
myopathy, and centronuclear myopathy), characterized histologically by 
central cores, multi-minicores, nemaline rods, central nuclei in muscle fibers, 
respectively; 
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- others myopathies (congenital neuromuscular disease with uniform Type 1 
fibers, and congenital fiber-type disproportion myopathy) characterized 
histologically by almost exclusive presence of Type 1 muscle fiber, relative 
hypotrophy of type 1 muscle fibers, respectively.  
Jungbluth et al. [2003] reported genetic, phenotypic and histopathological overlaps 
between different myopathies, and marked phenotypic variability. In particular, 
defects in more than one gene are associated with the presence of the same 
pathological feature, while defects in the same gene can result in more than one 
pathological feature (Tab. 3).  
 
 
Disease Gene MH risk 
Central core disease (CCD) 
 
RYR1 
ACTA1, MYH7 
High* 
Low 
Multiminicore disease (MmD) 
 
SEPN1, TTN 
RYR1 
Low 
High* 
Nemaline rod myopathy (NM) 
 
NEB, TPM3, TNNT1,TPM2, ACTA1, CFL2 
RYR1 
Low 
High* 
 
Tab. 3  Genes involved in core myopathies and  estimated risk of MH (given there isn’t cases of MH in 
the family) 
 
 
1.4.2.1 Central Core Disease (CCD) 
 
CCD (MIM 11700) is a rare hereditary myopathy, characterized clinically by muscle 
weakness of variable degree and histologically by central cores generally in the type I 
muscle fibers. The term central cores indicates areas with characteristic absence of 
oxidative enzyme activity in the muscle fiber as detected by NADH reductase staining 
(Fig. 12) [Dubowitz et al., 1960].  
The classic phenotype is characterized by mild hypotonia during early childhood, 
delayed motor milestones, and diffuse and moderate muscle weakness that 
frequently involves axial muscles. Congenital hip dislocation, early-onset scoliosis, 
arched feet, and pectus excavatus may also be present, whereas bulbar 
involvement, ophthalmoplegia, and diaphragmatic weakness are very rare. In 
adulthood, the syndrome usually is nonprogressive. Functional improvement can 
occur and approximately 40% of affected adults are considered asymptomatic. 
However, the evolution is unpredictable, and weakness may cause severe disability 
in daily life [Fischer et al., 2006; North et al., 2004].  
 
 
Fig. 12 Histopathologic appearance of 
typical central core disease: type 1 fibers 
containing unstructured cores (arrow) 
and no mitochondria (NADH reductase 
staining). Cores are typically well 
demarcated and centrally located, but 
may occasionally be multiple and of 
eccentric location (figure from Jungbluth 
et al., 2007). 
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Diagnosis. The diagnosis of CCD is based on the presence of suggestive clinical 
features and on histochemical staining of muscle biopsy samples that shows areas 
with reduced/absence oxidative activity, called central cores (Fig 12). The clinical 
severity of CCD and the number of cores can vary with age, making uncertain the 
diagnosis. Muscle magnetic resonance imaging (MRI) may show a characteristic 
pattern of selective muscle involvement and helps to confirm the diagnosis in cases 
with equivocal histopathologic findings [Jungbluth et al., 2004]. No curative therapy is 
currently available for congenital myopathies. The therapy of congenital myopathies 
is essentially supportive and/or rehabilitative. Physiotherapy is utilized for the 
maximum preservation of muscle power and function and the prevention of 
contractures, with particular care after surgical procedures. β-agonists, as the 
salbutamol, have been shown to be beneficial on muscle strength in patient affected 
by congenital myopathy [Messina et al., 2004]. Therapeutic assays with the 
salbutamol administration have been proven to significantly increase muscle strength 
in CCD patients. Salbutamol is also able to reduce muscle pain when present. In 
addition, patients affected by a CCD should be given general anesthesia cautiously 
because they can develop life-threatening MHS.  
 
Genetic basis. CCD is caused in the majority of cases by mutations in the RYR1 
gene, also implicated in the MH susceptibility. CCD is usually inherited as an 
autosomal dominant trait [Jungbluth, 2007] but autosomal recessive forms have been 
recently reported [Kossugue et al., 2007; Wu et al., 2006; Zhou et al., 2006b; Zhou et 
al., 2007). Dominant RYR1 mutations affecting the cytoplasmic N-terminal and 
central regions (domains 1 and 2) of the RYR1 protein give rise predominantly to the 
MHS phenotype characterized by highly responsive channels with massive Ca2+ 
release (Fig. 13 A), whereas the classical CCD phenotype, with few exceptions, is 
associated with dominant RYR1 mutations clustered in the hydrophobic C terminal 
pore-forming region of the protein (domain 3) [Robinson et al., 2006; Treves et al., 
2005]. There is a clear association between CCD and MH susceptibility: patients with 
CCD may be prone to MH episodes [Eng et al., 1978; Frank et al., 1980; Shuaib et 
al., 1987] and individuals with MHS may have central cores on muscle biopsy 
[Denborough et al., 1973]. Cases of the MH (~70%) and CCD (~50%) linkage to 
mutations in RYR1 gene suggested that the two conditions are allelic disorders 
[Zhang et al., 1993; Quane et al., 1993; Gillard et al., 1991]. 
In vitro studies demonstrated that two distinct cellular mechanisms can generate the 
muscle weakness in CCD patients. The leaky-channels hypothesis [Du et al., 2001] 
proposes that mutations in the RYR1 protein generate channels that are excessively 
leaky to Ca2+ and lead to depletion of SR Ca2+ stores, generating consequently 
muscle weakness (Fig. 13 B and C). The E-C uncoupling hypothesis [Dirksen and 
Avila, 2002] proposes instead that a deficit in E-C coupling, i.e., a reduced voltage-
gated release in the absence of detectable store depletion, lies at the base of muscle 
defects. The two hypotheses are not necessarily mutually exclusive. The discrepant 
results obtained so far indicate that the two mechanisms could coexist. However, 
these two hypotheses clearly do not explain all cellular and pathological phenotypes, 
that are overlapping in different congenital myophaties (see 1.4.3 for deepening).  
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Fig. 13  Schematic model of distinct cellular mechanisms generating MH (B) and CCD (C and D) 
phenotypes (figure modified from Brini et al., 2004). 
 
Central cores on muscle biopsy have been observed in a group of patients with 
hypertrophic cardiomyopathy secondary to mutations in the β-myosin heavy chain 
(MYH7) gene, however, these patients typically do not have associated muscle 
weakness or any other features of typical CCD [Fananapazir et al., 1993]. Central 
and minicores in association with a dilated cardiomyopathy may also rarely been 
observed in patients with mutations in the skeletal muscle α-actin (ACTA1) gene 
[Kaindl et al., 2004], more frequently associated with nemaline myopathy. 
 
 
1.4.2.2 Multiminicore Disease (MmD) 
 
MmD (MIM 255320) is a recessively inherited congenital myopathy morphologically 
defined by localized multiple areas of mitochondrial depletion and sarcomere 
disorganization, called minicores, running to a limited extent along the longitudinal 
axis of both type 1 and type 2 muscle fibers (Fig. 14) [Jungbluth et al., 2004]. 
Presentation of MmD is usually in infancy or childhood with hypotonia or proximal 
weakness; prenatal onset with reduced fetal movements and polyhydramnios has 
also been recognized [Jungbluth et al., 2000]. At least four clinical phenotypes have 
been associated with the presence of minicores: 1) the classic phenotype 
characterized by axial muscle weakness, commonly leading to severe scoliosis; 2) 
the classic MmD phenotype with also ophthalmoplegia; 3) predominant hip-girdle 
involvement, occasionally associated with arthrogryposis at birth, and 4) moderate 
forms with marked distal weakness and wasting predominantly affecting the upper 
limbs [Ferreiro et al., 2000].  
 
 27 
 
 
Diagnosis. The diagnosis of MmD is based on histochemical staining of muscle 
biopsy. MmD is characterized by multifocal, well-circumscribed areas with reduction 
of oxidative staining and low myofibrillar ATPase [Naguib et al., 2002]. In contrast to 
central cores, minicores extend only for a short distance along the longitudinal axis of 
the muscle fibre, are typically unstructured and may affect both type 1 and type 2 
fibres (Fig. 14) [Dubowitz et al., 2006]. As for CCD, the salbutamol has been used in 
some MmD patients with encouraging results [Messina et al., 2004], however, results 
of this pilot study will have to be validated in a larger randomized controlled. 
 
Genetic basis. MmD is genetically heterogeneous. The classic form of MmD is most 
frequently associated with mutations in the selenoprotein N1 (SEPN1) gene [Ferreiro 
et al., 2002a]. Selenoprotein, a glycoprotein localized in the ER, has recently been 
shown to be required for RYR1 Ca2+ release [Jurynec et al., 2008]. The SEPN1 gene 
mutations account for about 50% of cases with the classic MmD phenotype. Clinical 
subgroups other than the classic phenotype of MmD have now been associated with 
mutations in the RYR1 gene [Jungbluth et al., 2005] (Tab. 3). These can be 
homozygous, compound heterozygous, or heterozygous with monoallelic expression 
[Zhou et al., 2006; Jungbluth et al., 2005; Monnier et al., 2003]. The RYR1 gene is 
also a likely candidate for the severe form of MmD with neonatal onset and 
arthrogryposis. The majority of MmD-related RYR1 mutations are missense 
mutations and are spread across the RYR1 gene; few intronic splicing mutations 
have been recently reported [Zhou et al., 2007; Jungbluth et al., 2005; Monnier et al., 
2003]. Few functional data are available to understand the pathogenetic mechanisms 
of MmD-related RYR1 mutations and suggest a wide variety of alterations [Ducreux 
et al., 2006; Zhou et al., 2006b; Zorzato et al., 2007]. Studies of Ca2+ homoeostasis 
in EBV-immortalized lymphoblasts from patients carrying the RYR1 p.P3527S 
substitution [Ducreux et al., 2006] suggested uncoupling defects, whereas the 
p.V4849I substitution [Jungbluth et al., 2002] was associated with a small but 
significant effect on resting Ca2+ concentrations. E-C uncoupling was also indicated 
by complete loss of Ca2+ conductance in recombinant mutant RYR1 channels 
expressing the p.R109Y substitution [Zhou et al., 2006b] previously associated with a 
MmD and ophthalmoplegia phenotype [Jungbluth et al., 2005]. Marked reduction of 
the amount of the RYR1 protein suggests that  some RYR1 mutations identified in 
MmD patients may affect the expression and stability of the protein [Monnier et al., 
2003, Zhou et al., 2007]. Additional work will be required to further elucidate the 
molecular mechanisms underlying RYR1-related MmD. 
Fig. 14 Histology of multiminicore 
disease (NADH-TR staining). The 
cores (arrows)  are   multiple, poorly 
defined (figure from Klingler et al., 
2009). 
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Finally, autosomal recessive mutations in the titin (TTN) gene were identified in a 
novel early-onset myopathy with minicores, increased central nuclei, dystrophic 
features and a fatal cardiomyopathy [Carmignac et al., 2007].  
 
1.4.2.3 Nemaline rod Mophaty (NM)  
 
NM (MIM 161800) is a rare congenital myopathy with an incidence of about two 
cases per 100,000 live births [Sanoudou et al., 2001]. It is characterized by the 
presence of rods or nemaline bodies, which are purple inclusions in myofibers 
detected by modified Gomori trichrome (GT) technique (Fig. 15) [Fardeau et al., 
2004]. The distribution of rod bodies may be random, but they generally clustered 
under the sarcolemma, around nuclei, or inside nuclei. The rods lack ATPase 
histochemical activity cores. The clinical features are heterogeneous, ranging from 
severe neonatal cases to mildly affected adults. NM can be divided into the following 
forms: 1) severe congenital; 2) intermediate congenital; 3) typical; 4) mild, childhood-, 
or juvenile onset; 5) adult-onset; and 6) others rarely associated with 
cardiomyopathy. NM is characterized by generalized muscle weakness with facial 
involvement or predominant involvement of proximal limb and respiratory muscles. 
Feeding difficulties, severe respiratory impairment, and skeletal involvement 
(including arthrogryposis, scoliosis, or spinal rigidity) have been observed in the 
congenital or very early-onset forms. 
 
 
 
Fig. 15  Skeletal  muscle fibers of patient with NM. A. Accumulations of rod-shaped nemaline bodies 
are clearly present (GT stain). B. Few cores are seen in NADH-TR staining. 
 
 
Diagnosis can only be made by detecting the specific structural abnormality on a 
muscle biopsy. Accumulation of sarcomeric components (α−actinin and tropomyosin) 
and formation of nemaline bodies (rods) are seen as dark purple structures with GT 
stain (Fig. 15), and the NADH-TR stain revelas the cores as white unstained areas. 
 
Genetic basis. NM is inherited as an autosomal recessive or autosomal dominant 
trait [Wallgren-Pettersson et al., 1999], and sporadic cases have been reported 
frequently (63%). Six genes have been associated with NM, all encoding known 
components of skeletal muscle sarcomeric thin filaments: different disease genes 
have been identified: α-tropomyosin (TPM3), nebulin (NEB), ACTA1, β-tropomyosin 
(TPM2), muscle troponin T1 (TNNT1), and muscle cofilin 2 (CFL2). NEB and ACTA1 
appear to be the most common causes of NM [Wallgren-Pettersson and Laing, 2006] 
(Tab. 3). In many cases, there is no strict genotype/phenotype correlation, indicating 
clinical and genetic heterogeneity of the disease. In a few cases, mutations in RYR1 
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have also been associated with nemaline bodies. However, these nemaline bodies 
appeared together with central cores, indicating a mixed core-rod myopathy [Monnier 
et al., 2000; Pallagi et al., 1998; Scacheri et al., 2000]. 
 
 
1.4.2.4 Centronuclear myopathy (CNM)  
 
CNM is a rare CM morphologically characterized by numerous centrally located 
nuclei; additional but inconsistent histopathological features comprise a central zone 
either devoid of oxidative enzyme activity or with oxidative enzyme accumulation, 
radial strands surrounding the central area, type 1 fibre predominance and 
hypotrophy (Fig. 16). The clinical phenotype of CNM is highly variable. Proximal limb 
girdle, paraspinal muscles, ptosis and extraocular eye muscle have been reported in 
several patients; distal muscular weakness has been described rarely [Wallgren-
Pettersson, 2000].  
 
 
 
 
 
 
 
 
 
 
 
Fig. 16  Skeletal  muscle fibers of patient with CNM. A. Type 1 fiber atrophy, central nuclei and radial 
sarcoplasmic strands are seen by NADH-TR staining (figure from Fujimura-Kiyono et al., 2009). B. 
Presence of COX negative fibers underlied with the arrows (figure from Zanoteli et al., 2009) 
 
Genetic basis. CNM is associated with mutations in several genes, whose products 
are involved in endocytosis and membrane trafficking, and exists in X-linked (MIM 
310400), autosomal-dominant (MIM 160150) and recessive (MIM 255200) forms. 
Mutations in the MTM1 gene, which encodes myotubularin 1, have been identified in 
patients with the most severe form of CNM, inherited as X-linked trait [Laporte et al., 
1997; Laporte et al., 1996] (Tab. 3). The autosomal recessive form has its onset in 
infancy or early childhood, whereas the autosomal dominant CNM has later onset in 
early adulthood and presents with mild weakness and slow progression. The 
dominant form of CNM is associated with mutations in the DNM2 gene, which 
encodes dynamin-2 [Bitoun et al., 2005], whereas the autosomal recessive form has 
recently been associated with mutations in the BIN1 gene, which encodes 
amphiphysin 2 [Nicot et al., 2007]. Recently, a heterozygous dominant missense de 
novo RYR1 mutation (p.S4112L) was identified in a patient with histopathologic and 
clinical features of CNM [Jungbluth et al., 2007].                            
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1.4.2.5 Congenital neuromuscular disease with uniform Type 1 fibers (CNMDU1) 
 
CNMDU1 is defined as a rare form of congenital myopathy characterized by the 
almost exclusive presence of Type 1 muscle fiber (>99%) without any specific 
structural changes [Oh et al., 1983]. Clinically, CNMDU1 shares common features 
with congenital myopathy, including early onset, mild proximal muscle weakness. 
 
Genetic basis. Sato et al. [2008] reported that 40% of patients with a diagnosis of 
CNMDU1 is associated with mutations in the C-terminal domain of RYR1, and 
suggested that CNMDU1 is allelic to central core disease. Recently, Fujimura-Kiyono 
et al., [2009] reported indicated that CNMDU1 patients with RYR1 C-terminal 
mutations present clinical manifestations similar to those of CCD phenotype 
associated with RYR1 C-terminal mutations, regardless of the presence or absence 
of cores on muscle biopsy. Therefore they proposed that CCD and CNMDU are the 
same disease, and that the absence of cores may be attributed to muscle sampling, 
as the degree of affection could be different among muscles. Alternatively, cores may 
be formed in an age-dependent manner and in CNMDU1 cases and the muscle was 
biopsied before cores were formed. 
 
 
1.4.2.6 Congenital fibre type disproportion (CFTD) 
 
CFTD is a subtype of congenital myopathy in which consistent type 1 fibre 
hypotrophy (compared to type 2 fibres) is the main histological abnormality. Clinical 
phenotypes show hypotonia and diffuse weakness that may improve with age; 
other clinical features can include facial, bulbar, respiratory weakness, low body 
weight, multiple joint contractures, scoliosis, long, thin face, and high-arched 
palate. Ophthalmoplegia, cardiac disease, and mental retardation are rare. 
 
Genetic basis. Mutations in three genes (TPM3, SEPN1, ACAT1)  are associated 
with CFTD.  Clarke et al., [2008] identified RYR1 as the fourth gene associated with 
CFTD. In fact, they found in a CFTD patient a compound heterozygosity of a 
missense mutation, and a nonsense (silencing) mutation in the RYR1 gene. 
 
 
1.4.3 Molecular mechanisms in RYR1-related core myopathies 
 
Zhou et al., [2007] suggested potential molecular mechanisms implicated in the 
marked phenotypic variability observed in core myophaties associated with dominant 
and recessive RYR1 mutations. Dominant RYR1 mutations were mainly found in the 
C-terminal and rarely in the central domain of RYR1 gene [Zhou et al., 2007; Wu et 
al., 2006]. Most dominant CCD-related RYR1 mutations localize to the M8/M10 loop 
surrounding the pore helix region (Du et al., 2002), demonstrating the main role of 
this part of the protein in the pathogenesis of CCD; two dominant CCD mutations 
localized in or close to segment M6 implies the potential importance of this 
transmembrane domain for channel function and stability [Zhou et al., 2007]. Most 
patients with dominant C-terminal mutations have the classical CCD phenotype 
(variable degrees of proximal weakness, respiratory or extraocular involvement, 
orthopaedic complications, and scoliosis), and  showed a highly consistent pattern of 
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selective muscle involvement at magnetic resonance imaging (MRI) of muscle. 
Interestingly, patients carrying the same amino acid substitution show marked 
variation in age of onset and severity, suggesting either a nonstochastic distribution 
of mutant and wild-type RYR1 proteins or other modifying genetic factors. Most 
cases with dominant mutations had large cores, central or peripheral. Moreover, 
there isn’t a direct correlation between muscle weakness and the propensity to 
develop cores in RYR1-related myopathies. In fact, in one family harbouring a seven 
amino acid deletion (p.C4883_Y4889del) and chatacterized by profound muscle 
weakness, clear cores were not present at the light microscopy level, although they 
were identified on electron microscopy performed on the second muscle biopsy from 
the affected mother 30 years after the first, non-diagnostic biopsy. Interestingly, the 
finding that dominant MHS-associated RYR1 mutations may give rise to a congenital 
myopathy phenotype in the compound heterozygous or homozygous state suggests 
a combined deleterious effect on the tetrameric RYR1 protein [Zhou et al., 2007].  
In contrast to dominant RYR1 gene mutations, recessive RYR1 gene mutations were 
distributed throughout different domains of the protein, with variable clinical 
manifestations ranging from typical CCD phenotypes to generalized muscle 
weakness and wasting with associated external ophthalmoplegia, variable degrees of 
bulbar involvement and respiratory impairment. Some patients with typical CCD 
phenotype showed recessive RYR1 gene mutations previously associated at the 
heterozygous state in MHS patients [Zhou et al., 2007]. Recently, Carpenter et al., 
[2009] described the segregation of a non-synonymous change in RYR1 (p.R3772Q) 
in three Asian families. Patients with this mutation at the heterozygous state were 
typed MHS, whereas the patients with this mutation at the homozygous state were 
both MHS and affected by myopathy.  
Moreover, Zhou et al., [2006] showed that the RYR1 gene may undergo epigenetic 
allele silencing during human development and that some CCD patients had a 
monoallelic expression in skeletal muscle but not in other tissues. The monoallelic 
expression can unveil the presence of an apparently recessive mutation. This 
epigenetic mechanism is likely due to genomic imprinting. However, although it has 
been demonstrated that monoallelic expression of the RYR1 gene is associated with 
DNA methylation, the regulatory elements of this RYR1 monoallelic expression have 
not been localized yet. Similar epigenetic modifications of RYR1 expression could 
account for both the reduced penetrance and the phenotypic heterogeneity of RYR1-
linked muscle diseases [Zhou et al., 2006]. This mechanism may also account for the 
observation that several mutations affect the amount of mutant RYR1 proteins in 
skeletal muscle [Zhou et al., 2006]. While the amount of expressed RYR1 protein 
was normal in patients with a typical CCD phenotype, a marked reduction of RYR1 
protein in muscle biopsies from patients with more severe clinical phenotypes 
(generalized muscle weakness and wasting and external ophthalmoplegia) was 
observed. In these patients, a heterozygous RYR1 gene missense mutation was 
expressed on the background of a second non-transcribed allele, suggesting RYR1 
epigenetic silencing as an important aetiological mechanism in RYR1-related 
congenital myopathies [Zhou et al., 2006a]. Monnier et al., [2008] reported nine non-
consanguineous families affected by recessive forms of congenital myopathies with 
cores and moderate to very severe phenotypes and for which quantitative defects of 
RYR1 were evidenced in muscles. Mutations were identified on both alleles for all the 
affected patients, in particular null mutation was present in at least one allele and a 
missense mutation on the second allele. Null alleles resulted either from frameshift, 
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splicing, or nonsense mutations and generated either unstable mRNA or unstable 
RYR1 protein. The degree of severity of the clinical presentation depended on the 
functional expression of the second mutant allele. Therefore, in the families reported 
by Monnier et al., [2008] the loss of RYR1 expression was caused by mutations of 
the RYR1 gene that affected either the stability of the transcript or the protein 
processing and did not involve epigenetic silencing that has been proposed by Zhou 
et al., [2006] to explain monoallelic expression of RYR1.  
Zhou et al., [2006b] reported three families with clinical features of core myopathies 
and with compound heterozygous substitutions in the RYR1 gene. Functional 
properties of these RYR1 mutants were studied on myotubes carrying endogenous 
mutations. In one family the presence of the p.A1577T/ p.G2060C substitutions in 
trans leads to a decrease in the amount of RYR1 expressed in skeletal muscle, 
without noticeably affecting the functional properties of the recombinant RYR1 ion 
channel. The relative amount of the RYR1 protein in the muscle biopsy from one 
patient of the family was significantly decreased. Zhou et al., [2006b] proposed that 
the concomitant presence of both substitutions leads to a decrease in the stability of 
the RYR1 homotetramer causing a partial depletion of RYR1 channels in the skeletal 
muscle tissue of the patient. In an other family the compound p.R109W/p.M485V 
substitutions in cis also reduced the endogenous RYR1 expression level in muscle, 
but affected also the ability of recombinant channels expressing both substitutions to 
conduct Ca2+. In the third family the p.S71Y and p.N2283H mutations do not lead to a 
significant reduction in RYR1 protein content, but affected both channel stability and 
activity.  The clinical phenotypes of patients from the two families, where partial 
depletion of RYR1 channels, was found, were more severe compared with the 
patient from the third family.  
Rossi et al., [2007] reported the identification of a novel RYR1 mutation resulting in a 
premature truncation of the RYR1 protein, RYR1R4837fsX4839, in a MH proband. The 
histological analysis of muscle biopsy of the patient showed a clear prevalence of 
type 1 fibres (about 95%) and central core lesions in about 80% of fibres. This 
mutation was also found in two daughters of the proband with the same histological 
changes in skeletal muscle fibres, but both typed MHN by IVCT. However, neither 
the proband nor the two daughters exhibited myopathy, indicating that the central 
core lesions observed were sub-clinical and do not adversely affect muscle function. 
Studies of Ca2+ release and Ca2+ dependence of [3H]ryanodine binding showed that 
the homozygotic expression of RYR1R4836fsX4838 in HEK293 cells resultd in non-
functional RYR1 channels and the expression of RYR1wt/RYR1R4836fsX4838 resulted in 
channels with overall functional properties similar to those of wild-type RYR1 
channels. Homozygotic expression of mutated channels exhibited negligible 
[3H]ryanodine binding at different Ca2+ concentrations indicating that the truncation 
either results in a constitutively closed channel or a marked disruption in the 
ryanodine-binding site. Sucrose-density gradient analysis of recombinant RYR1wt, 
RYR1R4836fsX4838 and RYR1wt/RYR1R4836fsX4838 channels expressed in HEK293 cells 
suggested that the heterotetrameric channels were likely less stable than 
homotetrameric wild-type RYR1 channels. The effects of the RYR1R4836fsX4838 
truncation on E-C coupling RYR1 in skeletal myotubes, probably due to the reduced 
stability/assembly of these channels, may predispose individuals to MHS, although 
with only a low degree of penetrance (MHS status of the proband but not his two 
carrier daughters). This variable degree of penetrance for MHS might arise from 
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differences between individuals with regard to wild-type:mutant stoichiometry, 
presence or absence of other modifying genes, or a combination of both.  
 
 
1.4.4 Risk of MH associated with core myopathies 
 
Some RYR1 mutations are associated with the coexistence of MH and CCD 
phenotypes: MH triggering drugs are contraindicated in patients with CCD carrying 
these mutations. In fact, many CCD patients, that have developed clinical episodes 
of MH, were typed MHS by IVCT [Shuaib et al., 1987; Robinson et al., 2006]. 
However, some patients with diagnosis of CCD were typed MHN by IVCT [Halsall et 
al.,1996; Curran et al., 1999]. Since genotype-phenotype correlations are insufficient, 
it may be more appropriate to assume MH susceptibility in CCD patients and prefer 
the nontriggering anesthetics unless the patient was typed MHN. 
Patients with MmD linked to mutations in the RYR1 gene may be at risk of MH 
reactions as it has been reported in few cases [Koch et al., 1985; Osada et al., 2004]; 
minicores on muscle biopsy have also been noticed in few MHS subjects, but without 
clinical features of a congenital myopathy [Barone et al., 1999; Guis et al., 2004]. The 
functional effects of MmD-associated RYR1 mutations have been studied in HEK293 
cells and in immortalized lymphocytes [Zorzato et al., 2007]: some of these mutations 
result in increased triggered Ca2+ release whereas others do not. Moreover, there is 
considerable overlap between CCD and MmD, in the some patients with CCD 
present multiple cores or minicores on histochemical staining of muscle biopsy 
samples, and a time-related change in the morphology from minicores to cores has 
been described [Ferreiro et al., 2002b]. Although there is no definitive evidence to 
absolutely contraindicate volatile anesthetics in MmD, it may be appropriate to advise 
caution in patients with MmD with a RYR1 etiology. 
The association between typical NM (patients who exclusively present rod bodies) 
and MH is rather unlikely, because there are no reports in which patients with NM 
developed a severe MH crisis or were tested as MHS by IVCT. Some NM patients 
exhibit the histological feature of cores and rods in the same muscle biopsy; in these 
patients the nemaline bodies may be a secondary feature of CCD. The nontriggering 
anesthetics are preferred, since the CCD itself may represent the major risk factor for 
MH reactions [Davis et al., 2003; Scacheri et al., 2000; Monnier et al., 2000].  
As a pragmatic approach, the nontriggering anesthetics could be preferred in patients 
with core myopathy with a RYR1 etiology [Klingler et al., 2009]. Table 3 summarizes 
the genes involved in the core myopathy, underlying their genetic heterogeneity. 
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2 AIMS OF THE WORK AND EXPERIMENTAL DESIGN 
 
 
The aims of this study were: 
1) the screening of the RYR1 gene for the identification of sequence variants in 24 
MHS subjects, one CCD patient and one patient with minicores;   
2) the molecular characterization of the sequence variants identified;  
3) functional characterization of the RYR1 mutated channels. 
 
In order to reach this aims we used the following experimental design:  
1)     - genomic DNA extraction 
   - amplification of the 106 exons of the RYR1 gene 
   - denaturing high performance liquid chromatography (dHPLC) analysis of the 
amplicons 
   - direct sequencing of the amplicons with an altered dHPLC eluition profile; 
2)     - analysis of changes in charge, polarity or structure introduced by the amino 
acid replacements 
   - analysis of the conservation of the amino acid residues replaced across 
homologous proteins by BLASTP  
   - segregation of the sequence variants in families by restriction analysis or by 
direct DNA sequencing 
   - absence/presence of the sequence variants identified in 100 normal 
chromosomes of the same ethnic group by dHPLC analysis 
Regarding the insertion-variant identified: 
   - in silico protein structure prediction (Garnier and Octanol softwares) 
   - transcription analysis 
   - m-RNA semi-quantitative analysis 
3)     - infection of the lymphoblastoid cells derived from patients carrying the 
sequence variants with Epstein Barr virus (EBV) 
   - proton and calcium release measurements in response to the RYR1 activator  
4-CmC in immortalized B lymphocytes derived from patients by the metabolic 
microphysiometr assay and the flow cytometry, respectively. 
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3 MATERIALS AND METHODS 
 
 
3.1 Patients 
 
Twenty-four unrelated MHS subjects including 16 probands, who experienced an MH 
event during anesthesia, were enrolled in this study. The MHS status was assessed 
by the IVCT according to the protocol devised by the EMHG [European Malignant 
Hyperpyrexia Group, 1984; Ørding et al., 1997]. One patient was referred with 
myopathy and minicores and one patient with CCD. Informed consent was obtained 
for each patient according to a procedure established by the local Bioethics 
Institutional Committee. 
 
 
3.2 Genomic DNA extraction 
 
Genomic DNA was extracted with the “Nucleon” procedure (Amersham, UK) from 
peripheral blood samples and from immortalized lymphoblastoid cells. 
Blood  samples (3-10 ml) were collected in sodium EDTA tubes and the cells were 
lysed adding 4 volumes of Reagent A (10 mM Tris-HCl, 320 mM sucrose, 5 mM 
MgCl2, 1% (v/v) Triton X-100, pH 8.0) to the blood sample. The mix was stirred for 4 
min at room temperature and centrifuged at 1300 x g for 5 min.  
Immortalized B-lymphocytes (1 x 107 cells) were centrifuged at 600 x g for 5 min at 
4°C and the pellet was resuspended and lysed in 1 ml Reagent A. The mix was left 
on ice for 5 min and centrifuged at 1300 x g for 5 min.  
The cellular pellet derived from blood samples or from immortalized cells was 
resuspended in 2 ml of Reagent B (400 mM Tris-HCl, 60 mM EDTA, 150 mM NaCl, 
0.1% SDS, pH 8.0) and transferred to a 15 ml screw capped propropylene centrifuge 
tube. Sodium perchlorate solution (1 ml) was added and mixed to perform the 
deproteinisation. DNA was extacted adding chloroform (2 ml) and mixing by 
inversion. Nucleon resin was added and centrifuged at 1300 x g for 3 min. The upper 
phase was transferred to a clean tube and 2 volumes of absolute ethanol were added 
and mixed by inversion until the precipitate appears. Precipitated DNA was hooked 
out using a heat-sealed Pasteur pipette. DNA was placed directly into Tris EDTA (10 
mM Tris-HCl, 1 mM EDTA, pH 8) buffer. The DNA concentration was determined by 
the absorbanceat 260 nm (A260) (ε 0,1% =20). The ratio of the readings at 260 nm and 
280 nm (A260/A280) provides an estimate of the purity of DNA with respect to 
contaminants that absorb in the UV, such as protein. Pure DNA has an A260/A280 
ratio of 1.8-2.0. 
 
3.3 Polymerase chain reaction (PCR)  
PCR is a standard method to amplify DNA fragments [Mullis et al., 1987]. We used 
the Amplitaq DNA Polymerase (Applied Biosystems), a thermostable DNA 
polymerase, and we prepared a PCR master mix under the standard conditions listed 
below (Tab. 4). 
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Tab. 4  PCR amplification protocol.  
 
Reagents Final concentration 
10X PCR Buffer 1X 
dNTPs 0.8 mmol/l 
MgCl2 1.5 mmol/l 
Forward Primer 0.4 µg/ml 
Reverse Primer 0.4 µg/ml 
DNA  template 40 ng/µl 
Taq DNA Polymerase 0.02 U/µl 
Final Volume 50 µl 
 
 
We performed the PCR amplifications with Applied Biosystems GenAmp PCR 
System 9600. In order to avoid nonspecific amplifications we used the touchdown 
cycling condition (Tab. 5) [Roux et al., 1994]. The PCR amplification conditions for 
each RYR1 exon are shown in the table 6. 
 
Tab. 5  Touch-down cycling condition; Ta (annealing temperature). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial Denaturation 
 
94°C 5’ 
Denaturation 
 
94°C 20’’ 
Annealing 
 
Ta + 7° C with ∆ -0.5°C  
for each cycle 
40’’ 
14 
c 
y 
c 
l 
e 
s 
Elongation 
 
72°C 45’’ 
Denaturation 
 
94°C 20’’ 
Annealing 
 
Ta 40’’ 
25 
c 
y 
c 
l 
e 
s 
Elongation 
 
72°C 45’’ 
                Final elongation 72°C 7’ 
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Tab. 6  Primer sequences,  Ta (annealing temperature) of the PCR reactions, PCR pruduct size 
(bp) and temperatures of the dHPLC analysis for each RYR1 gene exon. 
 
exon forward primer  reverse primer  Ta 
amplicon 
size (bp) 
dHPLC 
temperatures 
1 GGGAGTCCTGGTCCAATG  CTCAGAGACCACCAGCAAGC 47°C 362 
 
 
62°C, 63°C, 64°C 
2 TGTGGTATCCGGGCCAGGCCC  CACCTCCTTTCAGACTCCCAGAACC 59°C 269 59°C, 64°C, 65°C 
3  CTCAAGAGTGTGGGCATCC GCCCTAAACGACCCCTGG 48°C 276 62°C,63°C, 64°C 
4  TGGAGAGTCCGGGGATCTGTGC GAGGTCAGCCTCCTTCTAGCAGGC 59°C 195 63°C, 65°C 
5 GAGTGCAACCTCGGTGGGCGTGG TCTCATGCTTGCCTTGGCGTTCTGC 61°C 255 63°C, 64°C 
6 GGCAGTGATAGGAGAGTTGTGGGCC  ACCTGGGAGCAGGAGGAACCGC 61°C 264 61°C, 62°C 
7 CTCGCCCACCCCTGCAATCG TATGCCTGAAGGGCAACATTAAGGG 61°C 217 62°C, 64°C 
8 TCCAGCCTCCCATTGACCAACTTCC TCATAGGGTCCCAGCCCTCCACG 61°C 198 62°C, 63°C 
9 ATTCCGGGGAGCTGAACCC CTTCCCCTCAAGACCTTTTCTGTCC 52°C 207 61°C, 62°, 63°C 
10 GGGGTCCTCTGACTCCCCTTGGC AGTGCAGGCTGGGCTGGGACGGG 64°C 257 64°C 
11 GCTCCCCTGCTAAACACAG CCTGGACTCAAGCGATTCTCC 61°C 279 
60°C, 61°C, 63°C, 
64°C 
12 GGGCAAGTGCAGAACTCAAGTC TTAGACAAGGGTGTGGGCAAC 52°C 231 62°C, 64°C, 65°C 
13 CGTTGCGGCAGTTAGCGC GCCCACAGGCCCGCTCCG 58°C 285 64°C, 65°C 
14 AGACAAGGAAGGGAGGGCCTGG GGTGTCAGATCCAATAGGACTGGG 59°C 265 60°C 
15 CCAGTCCTGACTCCCCTGAGAACACC TGCCCAGAATGAGAGGTTGAAGCG 59°C 244 61°C, 62°C, 63°C 
16 GAGGCTTGTGGGAGGGGATGG GGAGGAGCAGAGTTCTGGAGCCC 61°C 261 61, 62°C 
17 CAGGGTTCTTCTGTAGAGCCTGCC CTGGGGTCAGATGTTGAGAGCC 60°C 226 60°C, 61°C 
18 (I) TTGGCTCTCCTCTCTGCCTCTCCG TCATCGCCGACCCCGTTGCC 58°C 258 64°, 65°C 
18(II) AGCTCAGGCCACCCACTTGCG GACTTAGAAATGCTGGGGTCAATGG 59°C 202 63°C, 65°C 
19 TGGTTCTGTGGGACCTGTGACG GGTCTGAGGACTGGCCGTGG 61°C 282 63°C, 64°C 
20 TGATCCCCATTGTCCTTCCTTACCC CCTCGCCAGAAAACCTTTGCAGG 60°C 278 62°C, 63°C 
21 ATGGTGGGAAAGGGGGTGCT ATGACCCCTGACCTCCAACC 54°C 375 
61°C, 63°C,  
64°C, 65°C  
22 GTGGGGAGTGGGAAGGAAAG AATCCCTGTCCCCTCCATCC 54°C 275 61°C, 62°C, 63°C 
23 TGGAGACCCTGAGGCCGTGG TCGACCTCCCCAGCCCTTAGC 58°C 243 63°C, 64°C, 65°C 
24 (I) GCAGAGCCCGGAAGTGGAGGTGAGG TGCTGCGCTTGGTGGCTTCATCC 64°C 341 64°C, 66°C, 67°C 
24(II) CAGGGCTGGAGCTACAGCGCAGTG ATCGGGGCTGGGGTCAGAGTTGG 64°C 235 64°C, 65°C, 66°C 
25(I) CCAACTTCTCGATGTCTTGGGATC CGCATCTCGCCTGTGGTGAC 54°C 190 60°C, 61°C,  62°C 
25(II) CGCATCTTCCGGGCAGAGAAATCC    TGGGAGAGACCACAGGACCTGGCAG 66°C 217 63°C, 64°C, 65°C 
26 CCTTATCTCTCCATTTCTCTGTGTG AGAAGGGCAGTGCAGGGTTG 54°C 308 61°C, 62°C, 64°C 
27 CCAACTCTCCCATCCCTACCTCC AGCACTGTGGAAGGAAGGAGC 58°C 362 62°C, 63°C, 64°C 
28(I) TATGGCCTAATGGTGGCTCCGTGTG TTGCCGTTCTCTGCCTCGCTCC 55°C 376 63°C,64°C, 65°C 
28(II) GCACTTCCGCTGCACTGC  CAGGTTACTGTGGTTGCCTACTTG 49°C 341 
62°C, 63°C, 66°C, 
67°C 
29 ATATTGCGGTGGGAGGGCTGGGC GGGCAGCTACTGGGGACTGTCACAC 66°C 291 61°C, 62°C, 64°C 
30 GGGACCCGAGTCCCTGACTTC AGCTCTGACTGCCTCCTGCCCTC 64°C 279 61°C, 63°C, 64°C 
31 TTCCGGGAGCTTGGGGAAGGG TCCTGGGATGCTGGGACATGATGC 60°C 300 
60°C, 61°C, 62°C, 
63°C 
32 CCTCCCTCCAGCCCACCCGTTTG CCCCACATCTCCTGCCTCAGCCTG 68°C 194 61°C, 62°C 
33 CTGGAAGTGGTGTGGTGGGACAGAG AGGGGCACTGAGTGGGACCCAG 62°C 371 63°C, 64°C, 65°C 
34(I) GATGCAGGAGGCTCATTCATCTGTC GAAGTGGTGACTCCAACTCCCGG 64°C 427 63°C, 65°C 
34(II) GGAAGGAGCACAGAAAATGG TTTTGGGAATGTGGGAGAAG 52°C 357 62°C, 63°C, 64°C 
35 GGCCAGGGCCTGATGATG TCCCCACTGCCTGAGGACGAAG 58°C 426 60°C, 61°C 
36 TTCAAGGAAGTCCTGATGGTCTC GATGTTGAGGTTGGGGTTTAGACAG 60°C 318 62°C, 63°C,  
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37 TCTCAGAGTTCCTGCTTTG CCGATACTGTAGAGGGTTGT 46°C 269 58°C 
38 TGCACAAATAAATGAGTGTGTAAGT AGGCATGGGGCTACCCAC 53°C 282 59°C, 60°C, 61°C 
39 CCATGTGCCGACCTGCCCTGCATG GGGCCAGAAGTTGGGGAAGGGAATG 68°C 424 
63°C, 64°C, 65°C 
66°C 
40 CGCTGTCACAGTGGTGGCTATGGC AGCTCCCCAGCACCTGCCTGG 62°C 220 62°C, 63°C, 64°C 
41 CAGGGGAGGAGGCAGCCACAGAG GGAGTGTTTGTTGAATGAGTGAGC 58°C 286 63°C, 64°C 
42 TACAGACCAGAGGAGGCACCTGATCC AGGTGTCCCAAGCAGCCGGG 61°C 279 63°C, 64°C, 65°C 
43 GCTGAGCCCCAGGAGGAAGGTGG GGAGGTGTGTGACCAGTGACTCCG 61°C 259 63°C,64°C 
44 CATGAGACCCCCTTTCCCCATGCG GGGCGGGTTGCCCTATTGAGG 61°C 256 65°C,66°C 
45 TGCCTCCCCAACCCACCCACCTTC TGCCTGCCCTCCCTTCCCATCCTG 61°C 183 63°C,64°C,65°C 
46 GCTCTACCCTCCTGTGTGGTAAGGG GCATCACTCCTTCGCCAAGTTCC 61°C 252 62°C, 63°C 
47(I) GGTGCAGAGGGGATGGAACTTGGCG TGTCGGGCAGGAACCCCACGTC 64°C 231 60°C, 63°C, 64°C 
47(II) CATCCTTCGTGCCGGACCACAAG    TGCTGCTCTACCGTGACCCATCTCC 64°C 216 63°C, 64°C 
48 TGTGCAGCGGGCCTGATGTCC TGCCCCACCCTGAAGCCTGC 64°C 288 64,2°C, 65,2°C 
49 GATTCTACATCTTGTGCATTGTCCC GTAGGAGGGAAGAGCAAACCAGTGG 58°C 187 62°C, 63°C 
50 TGCCTGCCATTCGCTGGTGCC TTGCAGAACCTTCTCCTCCTTGAAC 57°C 315 59°C, 62°C 
51 GGGAGGAGGGCTGATGATTGCAGTG CAGCAGATGTTGGAGCTGGGGTTCC 70°C 343 60°C, 61°C, 63°C 
52 CGGCCTGTGGAGACCCTCAAGTG GGGCCTCAGGGAAGAACCAGGTC 66°C 269 61°C 
53 TGTCCTCGGCTCCTCCAGGG ATTGCCTCACTCCTCCCCGAATC  58°C 246 58°C, 59°C, 61°C 
54 TGGTCAGGGTTTTCTGCTTTG TCTCCTCTCCATCCCTTCCC 48°C 307 60°C, 61°C 
55 GTGGAGGGGGTAGAATGGAC AGCTCCTGCTTCTTCTTCCG 48°C 328 60°C, 61°C, 62°C 
56 GGGGGCTGGCATCCTCTGAA CGGTGAATCCACGGGGGTAGC 50°C 172 61°C, 62°C, 63°C 
57 GCAAGCAATGTTTCCGTTATTC TTAGCTCCTCCCCTCTGGTT 45°C 396 62°C, 63°C, 64°C 
58 GAGGGGAGAAGGGTAAGTG AGGGGAGGACGGATTGAGAG 51°C 395 61°C, 62°C 
59 ATTTCCCAACTCTGCTCCCA GAGATAAAGGGTCCAATGAG 45°C 238 60°C, 61°C 
60 CCCCTCATTGGACCCTTTAT TCAGTCCCGGGTACACTAGG 49°C 320 60°C, 61°C, 62°C 
61 CTGTCCTCGTCTCCTTGGC ATAGGTCTGTCTCTCCACT 48°C 335 59°C, 60°C, 61°C 
62 AGGAAGAGAGCGGTTGGGG GGCAGCGGGGGAACATCAG 50°C 256 61°C, 62°C, 63°C 
63 GCCCACTCCCACCATCATC CCACACATTCAAACACCCAG  52°C 430 61°C, 62°C, 63°C 
64 CTGCTTGCTCTTCCCCACTG CATCTACCCTGCTTTTCACC 50°C 285 63°C, 64°C 
65 GGGAGGAGCCGTTTCTATG CCCAGCCCAGCCACACTAC 50°C 317 63°C, 64°C, 65°C 
66 (I) TAGTTGGGTTGGAGGGTGAG TGAGGTGGTCAGAGGTGACA  58°C 410 58°C, 59°C, 62°C 
66 (II) CCCAACAGTGTGGAGGAGAT TGACCCCTGGTCTTTTGATG   56°C 468 62°C, 63°C, 64°C 
67 GAGATGCTGTTTGGGAGTCG AGATCAGATGGGGCTGGAG 50°C 400 63.8°C, 64.8°C 
68 GAAACCCCATCCCTCTGAC CACAAAGTTCTGCTCCTCGC 54°C 327 63°C, 64°C 
69 AGGAGCTGTTCAGGATGGTG GAGATGGGAGGAGGGAGAAG 48°C 449 60°C, 61°C, 62°C 
70 CCTTCTCAGGTCTCAGAGAA GGGTGGGGAACAGAAGCAGG 48°C 302 61°C, 62°C, 63°C 
71 CCTGGGGTGTGGATGATG GGGCTCAGTGGCATTGTGG 54°C 330 64°C, 65°C 
72 AAAACCTCTTCAGTTCCTGG GTAAATGCTCAAACCTTCACTA 50°C 254 59°C, 60°C 
73 TCACCCATTGAGTCCTCCCA AGACCCCACCCACATCCTTG 54°C 342 64°C 
74 TTCCTTCTGCCGTGTGAGTC GTGCTTCCCGACCTCCCAT 49°C 373 
61°C, 62°C, 63°C, 
64°C  
75 GAGAGTCTGGAGAATGGAGG GCCCTACTTTGGTTCTACTC 54°C 370 61°C, 62°C 
76 AAACCCTCTCCCCAAGTCTC CCCAGATTGCTGGGACTACA 51°C 293 61°C, 62°C, 63°C 
77 AGAGTGTTGGGATTACAGGC ACAAAGCAGACCCCTCCATC 58°C 259 61°C 
78 ATTTCCCTCTCCCCACCTGC TGCTCTGTGAACACATGCTG 49°C 250 61°C, 62°C 
79 TGAGAATGTGAGGGGGAAAG CAAACCACAGGCATTGAGGG 48°C 284 61°C, 62°C, 63°C 
80 TGGCTGTTTTTCTGGTGGGTG GGAGAAACTGGGAGTCACAC 50°C 226 60°C, 61°C, 62°C 
81 CAGGTAACAGAGGCAAAGGG AAGAGCAGAATCAGAACTGG 48°C 265 59°C, 60°C 
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82 GCTAAATGGGTGGTTTCTGG GGAGGAATCCCAAAGGAAGA  52°C 347 59°C, 60°C 
83 GCCTTTCTCTCTCTGTGGGTTG   GGGGAAAGTGAAGCTTAGGG 48°C 418 
59°C, 60°C , 61°C, 
62°C 
84 CAGTGTCTTTGGAGTGGCAG GGGCGGAAACTAATTCAGTC 52°C 306 61°C, 62°C, 63°C 
85 CTGGCATACAATAGGAACTC CCGAGTAGTACCAGTAGAAG 48°C 313 
58°C, 59°C, 63°C, 
64°C 
86 CACGGTTCAGGTGTGACTTG GCGCCCTACCTGGATGTACT 50°C 221 61°C, 62°C, 63°C 
        87 CTGGGGCGGGAGTGGGAAG CCCGGAAGCAGGTGGATGGA 59°C 239 63°C,  64°C 
88 GTAGGTGAGGAGGGGGAGAA CCCTCACTCCTGGGTGTTTA   52°C 182 61°C, 62°C 
89 CGACCTGACATCATTAGC CAAACAAGGAAAGTGAGG 46°C 532 60°C, 61°C, 63°C 
90 GAATTGAGGCTCTCCAGGTCACC TCTGAGGGTGCAGGAAGTGAGC 62°C 467 62°C, 64°C 
91(I) GCGGTGACCCCTTGTAGCTG AGGCTGCGGTAGCTGAGGCC 50°C 405 64°C, 65°C, 67°C 
91(II) CCGGAGACCGACGAGGACGA CTCGTCGCTGGTGGGGTCGG 61°C 390 
64°C, 70°C, 71°C, 
72°C 
91(III) TGCTCTGGGGCTCGCTGTTC GTGTGTGTCTCCACCCAGCC 55°C 453 61°C, 66°C, 68°C 
92 AAAGGAGATGAGAGGAGCAGG CTACTCTAGGAGGGAGGCAGTG 56°C 214 63°C, 64°C, 65°C 
93 GCCCTTGGTGAATGTTTTG  GGTTCTTCTTAGAGACGAGC 54°C 350 61°C, 62°C 
94 TTTGATTGCAGGTAAATGATGGGATG CCCTGAAATTCTGATAGGGGCTGAGC 58°C 262 59°C, 60°C, 61°C 
95 CCAGTCCAATCTCGGGAATGGAG CACCCAGCCAATAAGCCCTTGC 59°C 385 
 60°C, 61°C, 62°C, 
63°C 
96 TGCTGAGACTATGGTCCAGCCAAGG ATTACAGGTGTGAGCCACCGTGCC 61°C 315 62, 63°C 
97 TGTCGTGGCTGACAGCTCTGATCCC TGCCCAAGGTCACACACCAAGCAAG 62°C 216 60°C, 61°C 
98 TGCACCTCCCATTTCTCAC GAGAGATGCTTGAGTGTCAGACTC 45°C 320 63°C, 64°C 
99 ATCACAGCCCACAATGAGCG GGAGTCATTCTTTGGTCAGG 52°C 303 62°C, 63°C, 64°C 
100 TACCCTCCAGAGTGCTCCTCG GTTCAGTCCCTGTGGCTCTACC 59°C 379 61°C, 62°C, 63°C 
101(I) TAGAGCCACAGGGACTGAACCG    CTTGTTGTAGAACTTGCGGAAGAAG 58°C 187 62°C, 63°C,  64°C 
101(II) TGATGACCGTGGGCCTTCTG   TATTAACTCCTTCAACAGATGCGAG 49°C 192 61°C, 62°C 
102 CGAATGAATGAGTGACCAGTGTGC TTGACACCCGAGAGGTGACTTGCC 63°C 344 61°C, 62°C, 63°C 
103 GAGGGCAAGCCCTGGAGGTAGGTAGC GCAAGAGACATCAGAGTGGAGGCCC 61°C 232 61°C, 62°C 
104 GGAGGATATGGAGGTAGGTCATGTC AGTACCCCACTGCTGGCTATTG 58°C 270 61°C, 62°C, 63°C 
105 TTGGGCAACATAGCAAGACTTC CTTTTTACTGCCACCTACTGAC 54°C 231 58°C, 59°C 
106(I) CAACAGAGCAACACCCTGTC ACTAAGGGGCTTGCTGTGAG 54°C 254 57°C, 58°C, 59°C 
106(II) AAGAGAGATGTTGGGATTTC GAAACAATTCCTGGATGTCC 50°C 269 
58°C, 60°C, 61°C, 
62°C 
 
Each amplification reaction was checked by agarose gel electrophoresis with 
ethidium bromide staining. DNA molecular weight Marker IX (Roche) was used to 
determine the sizes of amplified fragments. 
 
3.4 Denaturing High Performance Liquid Chromatography (dHPLC)  
 
dHPLC is an ion-pair reversed-phase high-performance liquid chromatography (IP-
RP-HPLC) technique. It identifies sequence variants based on detection of 
heteroduplex formation between mismatched nucleotides in double-stranded PCR 
amplified DNA. Sequence variation creates a mixed population of heteroduplexes 
and homoduplexes during reannealing of wild-type and mutant DNA. When this 
mixed population is analysed by dHPLC under partially denaturing temperatures, the 
heteroduplexes elute from the column earlier than the homoduplexes because of 
their reduced melting temperature [Sivakumaran et al., 2003]. 
dHPLC analysis was performed using the WAVE system 3500 (Transgenomic, 
Omaha, NE). PCR samples from patients were mixed with equimolar amounts of the 
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wild type amplicon, denaturated at 95°C for 5 min and then cooled at room 
temperature to allow heteroduplexes to form if a mutation is present in the sample 
from the patient. Aliquots of each mixture (5-8 µL) were loaded onto a preheated C18 
reverse-phase column (DNASep 4.5 x 50 mm; Transgenomic). To enhance the 
probability of detecting sequence variations of the PCR products by dHPLC, we 
analysed the PCR products for heteroduplexes using two or three partially denaturing 
temperatures selected from the predicted fragment melting profile generated by the 
WaveMaker 4.1.40 software (Transgenomic). The temperatures of the analysis for 
each RYR1 exon amplicon are showed in table 6.  
 
 
3.5 DNA sequence 
 
Amplicons with an alterated dHPLC eluition profile compared to that obtained from a 
wild-type amplicon were direcly sequenced with dye-terminator chemistry (Applied 
Biosystems) using an ABI3100 automated sequencer (Applied Biosystems, USA). 
Nucleotide substitutions were numbered on the cDNA sequence (GeneBank 
NM_000540.2) and on the genomic sequence (AC011469.6, AC067969.1, 
AC005933.1 accession numbers) using the Mutalyzer program [Wildelman et al., 
2008]. 
 
3.6 EBV-transformed B-lymphocytes  
 
In order to obtain stable lymphoblastoid cell lines, human B lymphocytes were 
infected with the Epstein-Barr virus (EBV), according to standard procedures [Neitzel, 
1986].  
 
3.6.1 Production of the Epstein-Barr Virus  
The source of  EBV was the marmoset cell line, B95-8, which is chronically infected 
with the virus and can secrete viral particle into the culture medium. B95-8 cells were 
cultured at 1-3 x 106 cells/ml in RPMI medium (R 0883, Sigma-Aldrich), 
supplemented with 10% fetal bovine serum (FBS) (CH30160,03, Hyclone) and 1% L-
glutamine (G7513, Sigma-Aldrich) at 37°C, 5% CO2. In order to stimulate the B95-8 
cells to secrete the EBV in the culture medium, the cells were plated at 2 x 
105cells/ml and cultured for 3-4 weeks at 33°C, 5% CO2. The cell suspension 
cultures were centrifuged at 1300 x g for 10 min. These supernatants were filtered 
with a 0,22 mm pore diameter filter (Millipore) and aliquots were frozen at -80°C.  
 
3.6.2 Mononuclear cell isolation 
Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density 
centrifugation. Peripheral blood was diluted 1:1 with Phosphate Buffered Saline 
(PBS) and 7 ml of diluted blood were layered carefully on top of 3 ml Ficoll-Hypaque.  
After centrifugation for 30 min at 750 x g at room temperature, the upper layer was 
removed and the mononuclear cell layer was collected from the interface. The cells 
were transferred to a 15 ml test tube and 10 ml of PBS were added. The cells were 
centrifuged for 10 min at 250 x g at room temperature.  The cell pellet was washed 2 
times with PBS and the cell number was determined in a  Burker counting chamber. 
The cells were transformed with EBV or stored in liquid nitrogen. 
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3.6.3 EBV infection of human B lymphocytes 
For infection with EBV, mononuclear cells were suspended at 1,6 x 107 cells in 
culture medium containing 50% of the EBV supernatant [Neitzel et al., 1986]. 
Medium was replenished twice weekly, and the cultures were monitored for signs of 
transformation (increased cell growth, cell aggregates, or clumping), which were 
generally apparent within 3 to 8 weeks in successful cultures. Transformed cultures 
were grown to approximately 1 x 107 cells/ml, cryopreserved in heatsealed 
borosilicate glass ampules (~ 5 million viable cells for each ampule) and stored in 
liquid nitrogen.  
One of the problems of EBV-transformed cell lines is the instability of the cells 
derived. Therefore each transformed cell line was cloned. Cell suspensions were 
diluted to a concentration of ~ one cell per 0,5 ml of  culture medium. The cells were 
plated into 96-well plates, adding 100 µl of medium per well. The cultures were grown 
until ~ 103 cells/well, then transferred to a 24-well plate. Clones were expanded into 
flasks and stored in liquid nitrogen. All the EBV-immortalized lymphoblastoid cells 
carrying the RYR1 gene variants were analyzed to verify the presence of the 
nucleotide substitutions. 
 
 
 
3.7 RNA extraction from EBV-immortalized B-Lymphocytes 
 
Total cellular RNA was extracted from EBV-immortalized B-lymphocytes using 
QIAamp RNA Blood Mini kit (52304, Qiagen). The kit provides a silica–based 
membrane and a specialized high-salt buffering system that allows RNA species 
longer than 200 bases to bind to the QIAamp membrane. 
Immortalized cells (1 x 107 cells) were centrifuged at 400 x g for 10 min at 4°C and 
the pellet was lysed in 600 µL Buffer RLT that immediately inactivate RNases, 
allowing the isolation of intact RNA. The lysate was homogenated by a brief 
centrifugation through a QIAshredder spin column, then 1 volume of 70% ethanol 
was added to the column and the sample was transferred to a QIAamp spin column. 
During a brief centrifugation step RNA is bound to the silica membrane. To eliminate 
the contaminants, the column was washed first with 700 µL of Buffer RW1 and then 
by 500 µL of Buffer RPE. RNA was eluted in 30 µl or more of RNase-free water and 
stored at –80°C. RNA concentration and purity were determined by measuring in a 
spectrophotometer the absorbance at 260 nm (ε 0,1% =20). Pure RNA has an 
A260/A280 ratio of 1.9–2.1. The quality and integrity of RNA were verified by agarose 
gel electrophoresis. 
 
 
3.8 cDNA synthesis 
 
The SuperScript III first-strand synthesis system (18080-051, Invitrogen) was used  
to synthesize first-strand cDNA from total RNA extracts. The reaction was performed 
as follows: - 2,5 µg RNA were denatured at 65°C for 5 min in a mixture containing 5 
ng/µL of random hexamer primers and 1 mM of dNTPs (10 µL final volume) and then 
placed on ice for 1 min; - 10 µL of the cDNA Synthesis Mix (20 mM of dithiothreitol, 
2× RT Buffer and 20 U/µL of SuperScript III reverse transcriptase) were added to 10 
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µL  RNA/primers/dNTPs mixture and incubated at 25°C for 10 min to anneal the 
primers to the RNA template; - cDNA was synthetized at 50°C for 50 min and then 
the reaction was terminated at 85°C for 5 min; - finally RNA was removed incubating 
synthetized cDNA with 2 U/µL of RNase H at 37°C for 20 min; cDNA was stored at       
- 20°C or used immediately for PCR. 
 
 
3.9 Semi-quantitative PCR 
 
Semi-quantitative PCR reactions were performed using a Perkin Elmer 9600 
thermocycler with the following mix: 1,5 µL cDNA, 0,2 U/µL of AmpliTaq polymerase, 
0.1 mM of dNTPs mix, 1× buffer AmpliTaq, 1,5 mM MgCl2 and 0,2 ng/µL of each 
primer. To avoid genomic DNA amplification in the PCR reaction, primers were 
designed over the intron splice junctions (Tab. 7). The housekeeping β−ACTIN gene 
was used as a control for variations in the RNA input. 
 
Tab. 7 Sequences of theprimer used for semi-quantitative RT-PCR. The forward primers were 
labeled with one fluorescent dyes, PET and VIC  for the RYR1 and the β-ACTIN genes, respectively. 
 
Gene 
 
Forward (F) and reverse (R) primers (5’-3’) Location Gene Bank 
Accession No. 
Product 
size(bp) 
 
RYR1 
F     PET-tcacatgtacgtgggtgtcc 
R     gcacttggtctccatatcctc 
c.14788-14807 
c.14987-15007 
 
NM 000540  
 
220 
 
β-ACTIN 
F    VIC-cgtcttcccctccatcgt   
R   tgttggcgtacaggtctttg 
c.171-188 
c.954-973 
 
NM 001101.3 
 
803 
 
 
Reaction conditions used for semi-quantitative RT-PCR are shown in table 8. The 
amount of amplicons in subsequent PCR cycles was evaluated by capillary 
electrophoresis.  
 
Tab. 8  Reaction conditions used for semi-quantitative RT-PCR of 
RYR1 and β-ACTIN genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial Denaturation 
 
95°C 5’ 
Denaturation 
 
95°C 20’’ 
Annealing 
 
54°C  40’’ 
25 
c 
y 
c 
l 
e 
s 
Elongation 
 
72°C 45’’ 
                Final elongation 72°C 7’ 
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3.10 Capillary Gel electrophoresis (CGE)  
 
CGE is a technique that allows high-resolution separation of nucleic acids. The most 
important advantage of CGE, when compared to other liquid-phase separation 
techniques, is the analysis speed combined with the high separation efficiency [Smith 
and Nelson, 2003].  
RT-PCR products were separated o the ABIPRISM 3130 Genetic Analyzer. The 
matrix file (spectral calibration) was generated using a 5-dye system (FAM, VIC, 
PET, and LIZs standards). 1 µL of the amplified product and 0.5 µL of GeneScanTM-
500 LIZ size standard were added to 12 µL of deionized Hi-DiTM Formamide 
(Applied Biosystems), denatured at 95°C for 5 min, and then chilled on ice for 3 min. 
Samples were injected for 10 s at 3 kV and subjected to electrophoresis at 15 kV for 
25 min using the POP-7 polymer at 60°C. The data were collected using the 
ABIPRISM 3130 Data Collection Software application v1.1. Electrophoresis results 
were analyzed using ABIPRISM GeneScans Analysis Software v3.7.1.  
 
3.11 Proton release assay 
 
The increase in the extracellular acidification rate of immortalized lymphoblastoid 
cells in response to 4-CmC is mainly due to the activation of the RYR1 channel and 
has been used to characterize the functional defect of  RYR1 mutant channels [Zullo 
et al., 2009, see appendix]. We measured proton release using the Cytosensor® 
microphysiometer (Molecular Devices, San Diego) as described [Zullo et al., 2009; 
Klingler et al., 2002]. All experiments were carried out with repeated cycles of 9 min 
applications of 4-CmC (C55402, Sigma-Aldrich) with a stepwise increase from 200 
µM to 1000 µM, followed by a 9-min washout. The stock solutions of 10 mM 4-CmC 
(C55402, Sigma-Aldrich) were prepared for the experiments with the Cytosensor®. 
 
 
3.12 Calcium release assay 
 
The principle of flow cytometric Ca2+ flux measurement is based on changes in 
fluorescence intensity or emission wavelength of a fluorophore following chelating of 
calcium ions. The fluorescence intensity of fluo-3 increases upon binding Ca2+and 
that of Fura Red decreases;  the Fluo-3/Fura Red fluorescence signal ratio allows a 
ratiometric analysis of Ca2+ fluxes [Bailey et al., 2006].  
EBV-immortalized B-lymphocytes were incubated with two Ca2+ sensitive 
fluorophores, Fluo-3 AM and Fura-Red AM, for ratiometric analysis of Ca2+-release 
[Minta et al., 1989; Novak and Rabinovitch, 1994]. Fluo-3 and Fura Red dyes were 
used at concentration of 2,6 µM and were excited at 488 nm and the two emission 
signals were detected at 530/30 nm (Fluo-3) and 610/20 nm (Fura Red). The 
incubation was performed at 37°C, 5% CO2 for 30 min in the Iscove’s medium 
supplemented with 0.1% BSA and 1% L-Glutammine. The cells were washed once 
and resuspended in HBSS medium without Ca2+, 1mM EGTA at 1x106 cells/ml. A BD 
FACSAria cell sorter was used to measure Ca2+ fluxes in response to 4-CmC and 
thapsigargin (TG); the measurement was done at 37°C. Forward angle scatter 
signals (FSC), an indicator of cell size, and side angle scatter signals (SSC), an 
indicator of cell granularity, were displayed on a linear scale, with the forward scatter 
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adjusted to gate cells from debris (Fig. 17 A). Fluo-3 and fura-Red fluorescence 
values are recorded and displayed on a logarithmic scale (Fig. 17 B). For each 
experiment, the fluo-3/fura-red values were recorded for 2 min before the addition of 
the triggering agents to obtain the baseline. Cells were then exposed to 4-CmC or 
TG and the cellular responses were analyzed over a period of 5 min (Fig. 17 C). To 
obtain a kinetic analysis of the response to the triggering agents, we splitted in 50 
gates the dot plot display of fluo-3/fura-red values versus time (Fig. 17 D). The fluo-
3/fura-red mean values for each gate were calculated using the Becton-Dickinson 
analysis software (Fig. 17 E).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 A. Forward angle scatter signals was plotted versus side angle scatter signals and P1 gate 
was drawn to rule out debris. B. Fluo-3 fluorescence values were plotted versus fura-red fluorescence 
values, on a logarithmic scale. C. The cellular responses were analyzed as ratio between fluo-3 and 
fura-red fluorescence value over a period of 7 min; the arrow indicates the administration of triggering 
agent. D. The dot plot display of the fluo-3/fura-red fluorescence values versus time was splitted in 50 
gates to perform a kinetic analysis. E. Values of fluo-3/fura-red mean values calculated for each gate. 
 
The cellular responses to the drug (4-CmC or TG) were measured by integrating the 
Fluo-3/Fura Red fluorescence signals by SigmaPlot program. Lymphoblastoid cells 
from normal subject responded to 4-CmC by increasing the Fluo-3/Fura Red 
fluorescence signals (Fig. 18). 
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Fig. 18 Increase of Fluo-3/Fura Red fluorescence mean signals in the control B-lymphocytes 
stimulated with different concentations of 4-CmC. Error bars show the propagation of the SEM.  
 
3.13 Statistical analysis 
 
Results are reported as means and standard error of the mean (SEM) of at least 
three independent experiments. Significance of the differences between groups was 
evaluated by the Mann-Whitney test. Differences were considered to be significant 
when P<0.05.  
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4. RESULTS 
 
d-HPLC screening of the 106 exons of the RYR1 gene was performed in 24 MHS 
subjects, one CCD patient and one with minicores. Sequencing of amplicons with 
altered d-HPLC elution profiles revealed 14 sequence variants, an in-frame insertion 
variant (Tab. 9) and several known and novel polymorphisms (Tab. 10). Some results 
have been already published [Zullo et al., 2009, see appendix]. For each novel 
sequence variant identified we performed the molecular characterization (see 4.1) 
and we characterized the effect of nine RYR1 variants on the channel function (see 
4.2). The mutation rate was 57%, considering the known mutations and the putative 
causative variants identified in this study, each in a single patient, with the exception 
of the CCD patient who bears a double RYR1 variant. 
 
Tab. 9 RYR1 sequence variants identified in 24 MHS subjects, one CCD patient and one MmD patient 
screened. 
 
Exon Nucleotide change 
Amino acid 
change 
Role of 
mutation 
References 
15 c.1589G>A p.R530H MHS c.m.* 
Robinson et al. 
2006 
17 c.1840C>T p.R614C MHS c.m. 
Robinson et al. 
2006 
39 c.6488G>C p.R2163P MHS c.m.* 
Robinson et al. 
2006 
39 c.6502G>A p.V2168M MHS c.m. 
Robinson et al. 
2006 
40 c.6635T>A p.V2212D MHS p.c.m. Galli et al 2006 
43 c.7025A>G p.N2342S MHS c.m.* 
Robinson et al. 
2006 
44 c. 7035C>A p.S2345R MHS p.c.m. This thesis 
44 c.7112A>G p.E2371G MHS c.m.* 
Zullo et al.2009 
and this thesis 
46 c.7355G>C p.R2452P MHS p.c.m. Zullo et al.2009 
46 c.7361G>A p.R2454H MHS c.m. 
Robinson et al. 
2006 
63 c.9293T>A p.S3098I CCD c.m. This thesis 
85 c.11708G>A p.R3903Q MHS/ MmD p.c.m 
Galli et al. 2006/ 
Zullo et al.1009 
91 c.12700G>C p.V4234L MHS p.c.m. 
Robinson et al. 
2006 
95 c.13990T>C p.C4664R MHS c.m.* 
Zullo et al.2009 
and this thesis 
102 c.14772-14773ins TAGACAGGGTGTTGCTCTGTTGCCCTTCTT 
p.F4924-V4925ins 
RPAVAVLPFF CCD p. c.m. This thesis 
 
c.m.: causative mutation; c.m.*: causative mutation demonstrated in this study; p.c.m: putative 
causative mutation. Nucleotide numbering reflects cDNA numbering based on cDNA Ref Seq: 
NM_000540.2, with +1 corresponding to the A of the ATG translation initiation codon in the 
reference sequence. The initiation codon is codon 1. 
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Tab. 10 Polymorphisms detected in the patient population screened. 
 
Nucleotide change 
genomic cDNA 
Location 
Amino 
acid 
Ref SNP ID 
(NCBI) 
References 
g.27135G>T c.165+35G>T Intron 2   Zullo et al. 2009 
g.28716G>A c.270+27G>A Intron  3  rs3745843  
g.30855C>T c.573C>T Exon 7 p.D191 rs892054  
g.30876A>G c.594A>G Exon 7 p.L198 rs12985668  
g.30952_30953insC c.631+39_40insC Intron 7   Zullo et al. 2009 
g.35004T>C c.1077T>C Exon 11 p.A359 rs10406027  
g.41447T>C c.1441-24T>C Intron 13  rs7254832  
g.41778G>A c.1668G>A Exon 15 p.S556 rs2288888  
g.41811G>C c.1672+29G>C Intron 15  rs2288889  
g.44559C>G c.2167+30C>G Intron 18  rs2071086  
g.45499C>T c.2286C>T Exon 19 p.P762 rs3745847  
g.49592A>G c.2678-67A>G Intron 20  rs2304148  
g.52376G>A c.2920G>A Exon 24 p.V974M  
Zullo et al. 2009 
and this thesis 
g.52399G>A c.2943G>A Exon 24 p.T981 rs2228069  
g.52435C>T c.2979C>T Exon 24 p.N993 rs2228070  
g.55276C>T c.3456C>T Exon 26 p.I1152 rs11083462  
g.61548T>C c.4161-6T>C Intron 28  rs55845760  
g.64095C>T c.4443C>T Exon 30 p.N1481  Zullo et al. 2009 
g.72251C>T c.5360C>T Exon 34 p.P1787L rs34934920  
g.75487A>G c.5622A>G Exon 35 p.E1874  
Robinson et al. 
2006 
g.75714C>G c.5814+35C>G Intron 35  rs16972654  
g.76880A>G c.6039A>G Exon 37 p.K2013 rs2228068  
g.78776G>T c.6178G>T Exon 38 p.G2060C rs35364374  
g.80697C>T c.6384C>T Exon 39 p.Y2128  Zullo et al. 2009 
g. 80871C>T c.6548+10C>T Intron 39   Zullo et al. 2009 
g.82501C>T c.6599C>T Exon 40 p.A2200V  
Robinson et al. 
2006 
g.85932C>T c.7089C>T Exon 44 p.C2363 rs2228071  
g.85941C>T c.7098C>T Exon 44 p.P2366 rs2229147  
g.86189C>T c.7260C>T Exon 45 p.H2420 rs12973632  
g.86794G>T c.7324-48G>T Intron 45   Zullo et al. 2009 
g.87112G>T c.7500G>T Exon 47 p.A2500 rs2228072  
g.87139G>A c.7527G>A Exon 47 p.V2509 rs2071088  
g.87236C>G c.7614+10C>G Intron 47  rs2960323  
g.89143C>T c.7863C>T Exon 49 p.H2621 rs2229142  
g.89152C>T c.7872C>T Exon 49 p.R2624 rs1469698  
g.89234A>G c.7926+28A>G Intron 49  rs1469699  
g.90506G>A c.7977G>A Exon 50 p.T2659 rs2229144  
g.90953_90955delCCT c.8068-30_32delCCT Intron 50  rs10532729  
g.91034T>C c.8118T>C Exon 51 p.I2706 rs2960340  
g.91106T>C c.8190T>C Exon 51 p.D2730 rs2915951  
g.91571G>A c.8337G>A Exon 53 p.E2779 rs2915952  
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Nucleotide change 
genomic cDNA 
Location 
Amino 
acid 
Ref SNP ID 
(NCBI) 
References 
 
g.91610G>A c.8376G>A Exon 53 p.R2792  Zullo et al. 2009 
and this thesis 
g.91662A>G c.8400+28A>G Intron 53  rs2915953  
g.92216C>T c.8541+34C>T Intron 54  rs2960342  
g.92219T>G c.8541+37T>G Intron 54  rs2960343  
g.92221G>C c.8541+39G>C Intron 54   Zullo et al. 2009 
g.92236A>G c.8541+52A>G Intron  54  rs2915954  
g.92586T>C c.8589T>C Exon 55 p.S2863 rs2229146  
g.92620G>A c.8616+7G>A Intron 55   Zullo et al. 2009 
g.92635G>C c.8616+22G>C Intron 55   Zullo et al. 2009 
g.92672C>T c.8617-35C>T Intron 55  rs2960344  
g.92673T>C c.8617-34T>C Intron 55   Zullo et al. 2009 
g.92810T>G c.8692+28T>G Intron 56  rs2960345  
g.92960_92961insTCA c.8693-105_104insTCA Intron 56  rs35973146  
g.92996A>T c.8693-69A>T Intron 56   Zullo et al. 2009 
g.93055G>C c.8693-10G>C Intron 56  rs2915958  
g.93205T>A c.8816+16T>A Intron 57  rs2915959  
g.93231A>C c.8816+42A>C Intron 57  rs2960346  
g.94097_94098insC c.8932+34_35insC Intron 58  rs5828009  
g.97960G>A c.9172+114G>A Intron 61   
Zullo et al. 2009 
and this thesis 
g.98287C>T c.9173-21C>T Intron 61  rs2960338  
g.98321A>G c.9186A>G Exon 62 p.P3062 rs2071089  
g.98704G>A c. 9457G>A Exon 63 p.G3153R  Zullo et al. 2009 
g.102442G>A c.9674G>A Exon 65 p.R3225Q  Zullo et al. 2009 
g.105619C>T c.10188C>T Exon 67 p.D3396 rs2229145  
g.105655C>T c.10218C>T Exon 67 p.Y3406  
Robinson et al. 
2006 
g.105697G>A c.10259+7G>A Intron 67   Zullo et al. 2009 
g.109668G>T c.10440+122G>T Intron 69   Zullo et al. 2009 
g.8585C>T c.10687-7C>T Intron 72  rs2960354  
g.9458A>G c.10938-86A>G Intron 74  rs6508806  
g.15671C>G c.11266C>G Exon 79 p.Q3756E rs4802584  
g.17914C>T c.11608+201C>T Intron 83   Zullo et al. 2009 
g.24356T>A c.11754T>A Exon 85 p.T3918 rs45613041  
g.11427C>T c.13317C>T Exon 91 p.A4439  
Robinson et al. 
2006 
g.16392C>G c.13671C>G Exon 94 p.S4557 rs35959206  
g.32386G>T c.15021+37G>T Intron 105   
Zullo et al. 2009  
and this thesis 
 
Nucleotide location was determined using the Mutalyzer program [Wildelman et al., 2008) from the 
genomic sequences AC011469.6 (from intron 2 to intron 69), AC067969.1 [(from intron 72 to exon 85) 
and AC0059333.1 (from exon 91 to intron 105) and from cDNA sequence Ref Seq: NM_000540.2 
(nucleotides were numbered on cDNA with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. The initiation codon is codon 1). 
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4.1 Molecular characterization of sequence variants 
 
Nine sequence variants [c.1589G>A (p.R530H), c.1840C>T (p.R614C), c.6488G>C 
(p.R2163P), c.6502G>A (p.V2168M), c.6635T>A (p.V2212D), c.7025A>G 
(p.N2342S), c.7361G>A (p. R2454H), c.11708G>A (p. R3903Q) and c.12700G>C (p. 
V4234L)] were previously associated with MHS status [Robinson et al., 2006], among 
which three (p.R614C, p.V2168M, p.R2454H) were found to be MH-causative 
(www.emhg.org), and one, p.R530H, was reported [Robinson et al., 2006] as a 
personal communication without characterization data. The p.R3903Q sequence 
variant was found at the homozygous status in a patient who had myopathy 
associated to altered distribution of oxidative enzymes and minicores in muscle 
(biopsy analysis, Dr. F. Cornelio, Milan, Italy, personal communication). Five 
missense changes, c.7112A>G (p.E2371G), c.7035C>A (p.S2345R), c.7355G>C 
(p.A2452P), c.9293T>A (p.S3098I) and c.13990T>C (p.C4664R) (Tab. 9), are novel 
sequence variants; these were absent in more than 100 alleles of MHN subjects and 
resulted in changes of amino acid residues conserved in all the RYR isoforms of 
various species. We also identified the variants c.2920G>A (p.V974M) and 
c.9674G>A (p.R3225Q) (Tab.10), each detected also in one MHN individual, and 
c.9457G>A (p.G3153R) and c.6599C>T (p.A2200V), which did not segregate with 
the MHS phenotype in the pedigrees we analyzed. Therefore, these sequence 
variants are probably polymorphisms (Tab. 10). The variants p.E2371G and 
p.R2452P occurred in two single MHS subjects, whereas p.R530H,  p.S2354R and 
p.C4664R segregated with the disease in the family (Fig. 19). Family NA-15, in which 
p.C4664R segregated with the MHS phenotypes, also carried the p.R3225Q 
substitution, and subject II:2 had both sequence variants (Fig. 19 B). Moreover, we 
identified in a CCD patient, besides the variant p.S3098I, also a novel insertion 
variant c.14772_14773insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT 
(p.F4924_V4925insRQGVALLPFF); this variant was not detected in 100 alleles of 
MHN subjects and affect a protein region highly conserved across homologous RYR 
isoforms from different species. The segregation of the double RYR1 variant, 
p.S3098I and p.F4924_V4925insRQGVALLPFF, was not investigated because of the 
absence of DNA samples from relatives.  
 
 
 
 
 
 
 
 
 
Fig. 19 Pedigrees of families NA-33 (A), NA-15 (B) and NA-36 (C) showing the segregation of RYR1 
sequence variants, which are listed on the left of each panel. Solid symbols: MHS individuals identified 
by the IVCT; N: individuals MHN typed by the IVCT; ?: untested members of the pedigree; +/–: 
presence or absence of the sequence variants. The arrow indicates the index case who experienced 
an MH episode. 
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4.1.1 Molecular characterization of the double variant S3098I and 
F4924_V4925insRQGVALLPFF.  
 
The c.14772_14773insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT variant, 
identified in the RYR1 exon 102 of the CCD patient, results in the in-frame insertion 
of  10 amino acid (aa) residues (F4924_V4925insRQGVALLPFF). The DNA 
sequence analysis revealed the presence of two overlapping sequences due to the 
heterozygous status of the insertion. We confirmed the presence of this variant by 
two ARMS reactions with two insertion-specific primer pairs designed to amplify the 
allele with insertion. As expected, we obtained amplification products only in the 
samples from the CCD patient (Fig. 20).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20  ARMS-PCR system. A. Primers design and scheme of PCR products. B. Agarose gel 
electrophoresis of ARMS PCR products. Lane 1: DNA molecular weight Marker IX (Roche) Lanes 2, 5: 
PCR samples from the CCD patient; lanes 3, 6: PCR samples from wild type DNA; lanes 4, 7: mock. 
 
Interestingly, we found that the 30-nt inserted sequence corresponds to an inverted 
and complementary sequence of 25 bp located at the RYR1 intron 105. To study the 
probable mechanism generating this mutational event, we sequenced the entire 
RYR1 genomic region spanning from intron 102 to exon 106. Since no deletion of the 
transposed sequence was found in the CCD patient, we ruled out a conservative 
transposition event. Moreover, we did not find any nucleotide substitution in the 
mutated DNA which could have generated rearrangement breakpoints. Thus, we 
hypotized that this insertion variant could have arisen from a replicative transposition 
involving the intron sequence replication, and its inversion and transfer to the new 
site (Fig. 21). 
 
1       2        3       4        5       6      7 
234 bp
207 bp
PRIMER PAIR 1 PRIMER PAIR 2
TAGACAGGGTGTTGCTCTGTTGCCCTTCTTCGT
F102mut
R102mut
F102
R102
234 bp
207 bp
inserted sequence
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Fig. 21 A. Transposition scheme. A 25 bp sequence from the intron 105 
(TAGACAGGGTGTTGCTCTGTTGCCC) was duplicated and inserted in the exon 102 of the RYR1 
gene. B. Hypotized insertion meccanism: 1) 5’ protruding cut in the exon 102;  2) 25 bp duplicated 
sequence insertion; 3) fill-in synthesis and generation of 5 bp direct repeats (TTCTT). As result of this  
insertion event, 30  nucleotides were added to the exon 102 sequence.  
 
Effects of F4924_V4925insRQGVALLPFF insertion on the structure of the RYR1 
channel. To shed light on the possible structural changes introduced in the RYR1 
channel by the insertion variant, we analyzed the effect of this insertion on the RYR1 
structure by using 3D prediction softwares. The 10 aa insertion, 
F4924_V4925insRQGVALLPFF, lies in the M10 transmembrane segment (aa 
Val4914-Ile4937) of the RYR1 structure model proposed by Zorzato [Du et al., 2002] 
(Fig. 22). Secondary structure prediction by the Emboss’ Garnier software and the 
analysis of hydropathy by the Octanol software showed that the insertion causes an 
interruption in an α-helix structure (Fig. 23 A and B) and modifies the hydropathy plot 
of the M10 segment (Fig. 23 C and D).  
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Fig. 22 Predicted structure of the RYR1 C-terminal region. The insertion-variant (in green) identified is 
located at the M10 domain (A), an α -helix adjacent to the predicted channel pore (B). A. 
Transmembrane topology of rabbit skeletal muscle RYR1 in Du model [figure modified from Du et al., 
2002]. B. Secondary Structure Prediction. Predicted regions of hydropathy (dashed line) and a helix 
(continuous line) for the C-terminal region of RYR1. The position of the selectivity (sel) filter is also 
indicated. The G residues (highlighted in gray) are possible points of flexibility (figure modified from 
Samsò et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23 Secondary structure prediction of the M9-M10 domains in RYR1wt (A, C) and 
RYR1F4924_V4925insRQGVALLPFF (B, C). Emboss’ Garnier software (A, B): the M10 segment in 
the mutated channel shows an interruption in α-helix-structure. Octanol software (C, D): the insertion 
mutation modifies the hydropathy profile of the mutated channel. The arrow indicates the insertion site. 
RYR1wt
RYR1F4924_V4925insRQGVALLPFF
M9 M10
A
B
RYR1wt RYR1F4924_V4925insRQGVALLPFFC D
RQGVALLPFF
B
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Transcription analysis. Quantitative defects of RYR1 gene expression have been 
reported in some patients with core myopathi[Monnier et al., 2008; Zhou et al., 2006 
a; Zhou et al., 2006 b]. Therefore, we examined the allelic expression of the RYR1 
gene in the CCD patient. Total cellular RNA was extracted from the CCD patient and 
from wild type immortalized B-lymphocytes. cDNA was synthesized from RNA and 
used as template for the amplification of an RYR1 fragment (c.14658-14877, cDNA 
numbering) containing the insertion site. The amplicons from the CCD patient cDNA, 
separated by capillary gel electrophoresis, revealed two peaks of 220 bp and 250 bp, 
corresponding to the expected lengths of the wild type and mutated RYR1 alleles, 
respectively. The peak of  the mutated RYR1 allele was about 16% than wild type 
allele revealing an unbalanced allelic expression in the CCD patient (Fig. 24). 
 
 
Fig. 24 Capillary gel electrophoresis analysis of the amplicons derived from the CCD patient cDNA. 
The cDNA region amplified contains the insertion site. The electropherogram shows two peaks at 220 
bp and 250 bp, corresponding to the products from the wild type and the mutated alleles, respectively.  
 
The unbalanced allelic expression was confirmed by sequence analysis of c.9269-
9564 (containing the 3098 codon) and c. 14658-14877 amplicons. Both the 
electropherograms showed the presence of two-overlapping sequences, deriving 
from the mutated and wild type alleles, but the peaks from the mutated sequences 
are lower than those from the wild type sequences. The instability of the mutated 
transcript was illustrated by the disequilibrium between the levels of the wild type and 
the mutated sequences of the cDNA in comparison with the gDNA (Fig. 25). This 
data indicate that the double variant generated an unstable mRNA in the CCD 
patient. 
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Fig. 25 Sequence analysis of exon 63 (left side) and exon 102 (right side) regions from cDNA (upper 
side) and genomic DNA (lower side). The c.9293G>T variant is shown as non coding sequence 
obtained using the reverse primers. The c.14772_14773ins 
TAGACAGGGTGTTGCTCTGTTGCCCTTCTT variant is shown as coding sequence obtained using 
the forward primers. The nucleotide sequences are shown below the chromatogram peaks. The 
insertion is underlined. 
 
To determine whether the two sequence variants lay on a common or on a different 
haplotype allele, we performed the allele discrimination by amplifing hemizygous 
cDNA segments from a heterozygous template, with allele specific oligonucleotides 
(ASO) [Michalatos-Beloin et al., 1996]. Conventional approaches to haplotyping 
require the use of several generations to reconstruct haplotypes within a pedigree, 
but in our case DNA samples from relatives were not available. Since the 
transcription analysis revealed that the allele with insertion was expressed at a very 
low level, we designed an ASO reverse (wt-ASO-R) that anneals specifically to the 
allele without the insertion. The specificity of wt-ASO-R was checked by using this 
primer to amplify both the genomic DNA (g.30726-30853) and cDNA (c.14657-
14784) from the CCD patient and from a control subject (Fig. 26 A). In any case, only 
one product of 127 bp, corresponding to the size of the PCR product from the wild 
type allele, was obtained for the mutated and control sequences, confirming that the 
primer doesn’t amplify the allele carrying the 30-nt insertion. Therefore, the wt-ASO-
R was employed in a long-range RT-PCR to amplify a 6878 bp fragment (c.7906-
14784, containing the 3098 codon and the sequence corresponding to the exon 102) 
(Fig. 26 B). The long-range PCR products were used as template for the 
amplification of a shorter fragment containing the 3098 codon (c.9269-9564) and the 
sequence analysis showed the presence of the G nucleotide at the position 9293 
(Fig. 26 C). Therefore, the allele without insertion, selected in the ASO long-range 
RT-PCR, codifies for serine 3098. In conclusion, the missense variant in the exon 63 
is located in cis with the insertion variant.  
 
[c.14772-14773insTAGACAGGGTGTTGCTCTGTTGCCCTTCTT] 
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Fig. 26 RYR1 molecular haplotyping of the CCD patient. A. wt-ASO-R specificity assay. Left. Scheme 
of the PCR. Right. Agarose gel electrophoresis. Lane 1: PCR reaction from the wild type genomic 
DNA; lane 2 : PCR reaction from the CCD patient genomic DNA; lane 4: DNA molecular weight 
Marker IX (Roche); lane 5: PCR reaction from the wild type cDNA; lane 6: PCR reaction from the CCD 
patient cDNA; lanes 3, 7: mock reactions. B. Left Scheme of the allele-specific long-range PCR. 
Right. Agarose gel electrophoresis. Lane 1: DNA molecular weight Marker II (Roche); lane 2 : PCR 
reaction from the wild type cDNA; lane 3: PCR reaction from the CCD patient cDNA; lane 4: mock 
reaction. C. Left. Scheme of nested PCR using the allele-specific long-range products as a template. 
Right. DNA sequence of the amplicon derived from the CCD patient (complementary strand). 
 
 
m-RNA semi-quantitative analysis. To analyze the expression levels of each RYR1 
allele identified in the CCD patient we performed a semi-quantitative analysis of 
mRNA, isolated from B-lymphocytes of the CCD patient and of a control subject, by 
using the RT-PCR according to Breljak et al. [Breljak et al., 2005]. We  carried out 
kinetic analysis on RYR1 and β-ACTIN cDNAs, as a reference gene, by amplifying 
PCR products over different number of  PCR cycles. The PCR products were 
separated by capillary gel electrophoresis. PCR reactions were exponential between 
24-27 and 19-22 cycles for RYR1 and β-ACTIN genes, respectively (Fig. 27 A). The 
logarithm of the fluorescence signals for each gene was plotted versus the 
corresponding number of PCR cycles of the exponential phase; the data points were 
processed by linear regression analysis [Breljak et al., 2005]. The expression levels 
of RYR1 and β-ACTIN genes in samples from the CCD patient and from the control 
were derived from the intercept of the regression line with the Y-axis (after 25 and 20 
cycles for RYR1 and β-ACTIN genes, respectively; Fig. 27 B). The fluorescence 
 1  2  3  4  5  6  7  
PCR: allele-specific long-range PCR products as  template 
c.9292-9294 (3098 codon)
c.9564c.9269
220 bp
C
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F
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F
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Wt-ASO-R Wt-ASO-R
1  2  3  4  5  6  7 
c.14784c.7906
F
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values at the intercept of the regression line with the Y-axis represent the mRNA 
levels. The total levels of RYR1 mRNA in the CCD patient (normalized versus β-
ACTIN) are about 89% of the control (normalized versus β-ACTIN), and the wild type 
allele represents the 76%  and the mutated allele with the insertion about 13% (Fig. 
27 C). Interestingly, the expression of RYR1 gene in the CCD patient is about 89% of 
the control, although the mutated allele is very low expressed (about 16%, Fig. 25).  
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Fig. 27 Relative quantification of RYR1 mRNA. RNAs isolated from B-lymphocytes were reverse 
trancripted and the RT-PCR products were analyzed by the capillary gel electrophoresis. A. The log of 
fluorescence signals for the RYR1 and β-ACTIN genes (left and right, respectively) were plotted 
against the number of PCR cycles. RNAs from the CCD patient and from the control were analyzed. 
B.  The logarithm of the fluorescence signals for each gene was plotted versus the corresponding 
number of PCR cycles of the exponential phase; the expression levels of RYR1 and β-ACTIN genes in 
samples from the CCD patient and the control were derived from the intercept of the regression line 
with the Y-axis (25 and 20 cycles for the RYR1 and β−ACTIN genes, respectively). C. RYR1 mRNA 
level in the CCD patient (normalized versus β−ACTIN gene) are expressed as percentages of the 
control. Each experiment was performed in triplicates. Error bars show the propagation of the SEM. 
 
 
4.2 Functional characterization of sequence variants  
 
We characterized the functional alterations caused by nine RYR1 sequence variants 
in EBV-immortalized lymphoblastoid cells by: 
- a metabolic assay based on the measurements of proton release in response 
to the RYR1 activator 4-CmC [Zullo et al 2009, see appendix]; 
- flow cytometry based on the measurements of calcium release in response to 
the RYR1 activator 4-CmC. 
 
Proton release measurements. The increased acidification rate of lymphoblastoid 
cells in response to 4-CmC was characterized and reported to be mainly due to 
RYR1 activation [Zullo et al., 2009; Zullo et al. 2007; Zullo, 2006]. Therefore, this 
assay can be used to analyzed the activity of RYR1 in this cellular system. B-
lymphocytes from patients with RYR1Arg530His (subject II:1 of family NA-33, Fig. 19), 
RYR1R2163P (proband of family NA-3 [Fortunato et al., 2000]), RYR1N2342S, RYR1S2345R 
(proband of family NA-36, Fig. 19), RYR1E2371G, RYR1R2454H and RYR1C4664R variants 
were available and were immortalized with EBV. As for the RYR1C4664R variant, three 
cell lines, MHS5, MHS6 and MHS7, were prepared from subjects II:1, II:2 and II:3, 
respectively, of family NA-15 (Fig. 19). Two cell lines were used as controls, named 
MHN1 from an unrelated MHN subject and MHN10 from subject II:2 of family NA-33 
(Fig. 19). Metabolic responses to 4-CmC were significantly higher in the cell lines 
harboring RYR1 channels with the sequence variants located at the N-terminus and 
at the central regions of the protein than in wild-type RYR1 cell lines (Fig. 28). On the 
RYR1 (wild type +
mutated alleles)
0
20%
40%
60%
80%
100%
RYR1 mutated
allele
N
o
rm
a
li
z
e
d
R
Y
R
1
 m
R
N
A
le
v
e
l
in
 t
h
e
C
C
D
 p
a
ti
e
n
t
(%
o
f
th
e
 c
o
n
tr
o
l )
RYR1 wild type
allele
C
N
o
rm
a
li
z
e
d
R
Y
R
1
 m
R
N
A
le
v
e
l
in
 t
h
e
C
C
D
 p
a
ti
e
n
t
(%
o
f
th
e
 c
o
n
tr
o
l )
N
o
rm
a
li
z
e
d
R
Y
R
1
 m
R
N
A
le
v
e
l
in
 t
h
e
C
C
D
 p
a
ti
e
n
t
(%
o
f
th
e
 c
o
n
tr
o
l )
N
o
rm
a
li
z
e
d
R
Y
R
1
 m
R
N
A
le
v
e
l
in
 t
h
e
C
C
D
 p
a
ti
e
n
t
(%
o
f
th
e
 c
o
n
tr
o
l )
 58 
contrary, the metabolic responses to 4-CmC were lower in the three cell lines 
carrying RYR1C4664R than in controls (Fig. 28). However, the response to 800 µM 4-
CmC of the MHS6 cell line with two substitutions, p.R3225Q and p.C4664R, each 
transmitted from one parent (Fig. 28), did not significantly differ from controls. The 
basal metabolism was unaffected, since the acidification rate of all the three cell lines 
expressing RYR1C4664R  recorded in the absence of 4-CmC was indistinguishable 
from that of the MHN control cells (data not shown). Mutations in the C-terminal 
membrane-spanning domain have been reported to show a smaller TG induced 
increase in cytosolic [Ca2+], in the absence of external Ca2+, than controls [Treves et 
al., 2008; Lynch et al., 1999]. This result has been taken to indicate Ca2+ store 
depletion due to “leaky” mutant RYR1 channels, since the signal obtained with the 
SERCA blocker reflects the size of the rapidly releasable intracellular Ca2+ stores 
[Tilgen et al., 2001]. To determine if the RYR1C4664R variant reacts in a similar way, 
we analyzed the acidification response of the MHS5 cell line to the TG. The early 
increase (in the first 2 min) after treatment with the SERCA pump blocker was about 
50% lower (data not shown) in this cell line than in the control. This result is 
consistent with partial Ca2+ store depletion in the cell line expressing RYR1C4664R, as 
confirmed by Ca2+ release measurements (see calcium release measurement).  
 
 
 
 
 
 
 
 
 
 
Fig. 28 Increase in the acidification rate of RYR1 variants. The increase in the acidification rate value 
of lymphoblastoid cells from normal subjects is taken as 100. Cell lines carrying RYR1 variants 
p.R530H, p.R2163P, p.N2342S, p.S2345R, p.E2371G, p.R2454H, p.C4664R and 
p.C4664R/p.R3225Q were stimulated with 400 µM, 600 µM or 800 µM 4-CmC as indicated. Each 
block of three bars corresponds to a cell culture preparation derived from a RYR1 variant patient as 
indicated. MHS5, MHS7 and MHS6 correspond to three different cell lines (see text). Error bars show 
the propagation of the SEM; asterisks indicate responses significantly different (P<0.05) from the 
controls. 
 
 
Calcium release measurements. The Ca2+  responses to 4-CmC of B lymphocytes 
derived from MHS and control individuals showed significant differences [Girard et 
al., 2001; Sei et al., 2002]. In the human B cell line, Ca2+ release in response to 4-
CmC can be a sensitive indicator of RYR1 function since RYR1-mediated Ca2+ 
signals can be pharmacologically distinguished from other intracellular sources in 
human B cells, as the IP3-sensitive stores and the mitochondrial stores [McKinney et 
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al., 2006]. We investigated the Ca2+ release in response to the stimulation with 4-
CmC and TG in immortalized B-lymphocytes carrying RYR1C4664R, 
RYR1S3098I/F4924_V4925insRQGVALLPFF, and MHN control cell lines using a flow cytometric 
technique. The Ca2+ fluxes were measured by integrating the ratio of the Fluo-3/Fura 
Red fluorescence signals. 
B-lymphocytes carrying the RYR1C4664R mutated channel revealed a 4-CmC (to 600, 
800 and 1000 µM)- and a TG-triggered Ca2+ release significantly lower than the 
control cells showing that the Ca2+ stores of the cell line expressing RYR1C4664R are 
partially depleted. In particular, the TG-triggered Ca2+ release in RYR1C4664R channel 
is about 50% lower than in the control. Therefore the p.C4664R variant leads to a 
leaky channel, since the Ca2+ stores are partially depleted. (Fig. 29). These data 
confirmed the results obtained by proton release assay (see Proton release 
measurements)  [Zullo et al., 2009].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 29 Fluo-3/Fura Red fluorescence signals ratio in response to 4-CmC or to TG. Cell lines carrying 
RYR1 variant p.C4664R (pink) and control cells (blue) were stimulated with 4-CmC (200 µM to 1000 
µM) or 1 µM TG. Ca2+ release were measured by integrating the ratio of the Fluo-3/Fura Red 
fluorescence signals. Experiments were carried out at least 7 times. Error bars show the propagation 
of the SEM; asterisks indicate responses significantly different (P<0.05) from the controls. 
 
 
B-lymphocytes expressing  the RYR1S3098I/F4924-V4925insRPAVAVLPFF channel showed a 4-
CmC (600, 800 and 1000 µM)-triggered Ca2+ release significantly higher than the 
control cells (Fig. 30). Moreover, the TG-triggered Ca2+ release was not significantly 
different from the control cells (Fig. 30), indicating that the RYR1 mutated channel is 
not a leaky channel. 
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Fig. 30 Fluo-3/Fura Red fluorescence signals ratio in response to 4-CmC or to TG. Cell lines carrying 
RYR1S3098I/F4924-V4925insRPAVAVLPFF (red) and control cells (blue) were stimulated with 4-CmC (200 µM to 
1000 µM) or 1 µM TG. Ca2+ release were measured by integrating the ratio of the Fluo-3/Fura Red 
fluorescence signals. Experiments were carried out at least 8 times. Error bars show the propagation 
of the SEM; asterisks indicate responses significantly different (P<0.05) from the controls.  
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5. DISCUSSION 
 
RYR1 gene screening showed that no RYR1 sequence variant is prevalent in MHS 
subjects and families from southern Italy. We examined the function of RYR1 
channel variants in EBV-immortalized lymphoblastoid cells by proton or calcium 
release assays. RYR1 is expressed in human B lymphocytes where it functions as a 
Ca2+-release channel during the B-cell receptor–stimulated Ca2+ signaling process 
[Sei et al., 1999], and Ca2+ homeostasis is altered in B cells of MHS individuals [Sei 
et al., 2002; Girard et al., 2001]. The increase in the acidification rate of immortalized 
lymphoblastoid cells in response to 4-CmC is mainly due to the activation of the 
RYR1 calcium channel, and this assay can be used to analyze the activity of RYR1 
[Zullo et al., 2009]. The metabolic responses of mutant RYR1 channels analyzed in 
this study were of two types, i.e. increase or decrease of proton release rate 
compared with the wild-type channel. The response seems to depend on the location 
of the mutation. The metabolic response was higher in RYR1 channels with 
mutations located in the N-terminal and the central regions of the protein, and these 
higher metabolic responses can account for the MHS phenotype.  On the contrary, 4-
CmC-induced activation was significantly lower in the cell lines harboring the 
RYR1C4664R mutated channel, and our results obtained by two different methods, 
proton and calcium release assays, indicate that p.C4664R leads to a leaky channel 
with depletion of intracellular stores. The p.C4664R mutation is located at the C-
terminal region of the protein in the M6 transmembrane segment [Zorzato et al., 
1990]. Other mutations at the C-terminus of RYR1 and associated with the CCD 
phenotype have been reported to lead to channels that are non- or hypo-reactive to 
chemical stimulation [Brini et al., 2005; Ducreux et al., 2004; Tilgen et al., 2001; 
Lynch et al., 1999]. In contrast, the p.T4826I mutation, associated to the MHS 
phenotype, was reported to have a higher 4-CmC and caffeine sensitivity compared 
to the wild-type RYR1 in transfected human myotubes [Yang et al., 2003]. The 
p.C4664R mutation has been identified in an MH family (Fig. 19) and no signs of 
myopathy compatible with CCD were found in the medical history of the patients. 
Howewer, a core myopathy could develope late in the life. In fact, recently was 
reported a patient (77 years old) with a novel RYR1 mutation (G40V) associated with 
pathologic features of a core myopathy and onset of symptoms at 60 years 
[Jungbluth et al., 2009]; therefore, patients with MH mutations may develop overt 
skeletal muscle involvement later in life.  
We identified in a CCD patient the compound 
p.S3098I/p.F4924_V4925insRQGVALLPFF substitutions in cis. Most dominant CCD-
related RYR1 mutations are localized to the M8/M10 loop surrounding the pore helix 
region (Du et al., 2002), that is involved in the channel function and regulation. The 
insertion variant identified is located at the M10 domain of the RYR1 channel and it 
could have arisen from a replicative transposition (Fig. 21). The double variant 
generated an unstable mRNA in the B-lymphocytes of the CCD patient:  the mutated 
allele is expressed at 16% in comparison with the wild-type allele. Interestingly, the 
total RYR1 gene expression in the CCD patient is about 89% of the control, although 
the mutated allele is very low expressed (Fig. 25). This finding indicates a positive 
regulation of the wild-type allele transcription of the RYR1 gene in the B-lymphocytes 
of the CCD patient. B-lymphocytes expressing  the RYR1S3098I/F4924-V4925insRPAVAVLPFF 
channel showed a 4-CmC-triggered Ca2+ release significantly higher than the control 
cells (Fig. 30). Moreover, the TG-triggered Ca2+ release was not significantly different 
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from the control cells (Fig. 30), indicating that the RYR1 mutated channel is not a 
leaky channel. Some RYR1 gene mutations identified in CCD patients generate 
channels that are excessively leaky to Ca2+ and lead to depletion of SR Ca2+ stores; 
other RYR1 gene mutations identified in CCD patients generate channels with a 
deficit in E-C coupling, i.e., a reduced voltage-gated release in the absence of 
detectable store depletion [Dirksen and Avila, 2002]. The RYR1S3098I/F4924-
V4925insRPAVAVLPFF mutated channel displayed hyperactivation by chemical stimulation 
in lymphoblastoid cells.  This behaviour is usually associated with the MHS 
phenotype. Although the MH susceptibility was not investigated in this CCD patient, 
the CCD condition is frequently associated with the MH susceptibility. The future 
prospective of this work is the study of the E-C coupling of the RYR1S3098I/F4924-
V4925insRPAVAVLPFF mutated channel in transfected myotubes to investigate if the 
development of the myopathy in this patient could be ascribed to an altered E-C 
coupling. 
RYR1-related diseases present genetic, phenotypic and histopathological overlaps 
and marked phenotypic variability, therefore molecular and functional studies of novel 
sequence variants of RYR1 gene contribute to clarify genetic basis and molecular 
mechanisms in RYR1-related disease. 
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